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 Abstract 
Paper I. The aim was to elucidate if testosterone (T) dose-dependently increase muscle size in 
abdomen and pelvis, analogous to the known anabolic influence on appendicular muscles. 
Participants were young (age 18-50) healthy men participating in the 5a-reductase trail, a double 
blinded RCT. Endogenous T production was supressed and replaced with four dosages (50, 125, 300, 
or 600 mg) of T enanthate. Magnetic Resonance Imaging scans from baseline and end of study was 
used to analyse change in muscle areas of the lower trunk and pelvis. The estimated change (95% CI) 
of muscle area increase per 100 mg of T enanthate dosage increase was 0.622 cm2 (0.394, 0.850) for 
psoas; 1.789 cm2 (1.317, 2.261) for paraspinal muscles; 2.530 cm2 (1.627, 3.434) for total abdominal 
muscles; 0.455 cm2 (0.233, 0.678) for obturator internus; 0.082 cm2 (0.003, 0.045) for 
ischiocavernosus. Areas were also associated on-treatment T and free T levels. In conclusion, the 
abdominal and pelvic muscle are responsive to T administration, opening up for future studies 
regarding T treatment in frail men with risk for falls and men with pelvic dysfunction. 
Paper II. Preoperative radiotherapy (RT) is used in treatment of rectal cancer (RC) to enhance local 
control. Acute testicular failure with risk for permanent damage to T production is a less known 
adverse effect of RT. The aim was to elucidate long-term effects on T production, and the association 
of elevated luteinizing hormone (LH) and cancer recurrence. This was a longitudinal prospective 
cohort study including men with rectal- or prostate cancer stage I-III. Exposure was RT, quantified 
by mean cumulative testicular dose (TD). Testicular function was assessed by sampling of T, LH and 
follicle stimulating hormone (FSH) at baseline and at follow-ups after one and two years. Exposed 
men were additionally sampled preoperatively. Within two years after surgery, T levels recovered, but 
LH and FSH levels were significantly higher in exposed. Changes in LH and FSH were related to 
TD.  Elevated LH one year after surgery inferred an incidence rate ratio for cancer recurrence in five 
years of 3·19 (95% C.I.: 0·97-11.2, mid-p=0·036) 
Paper III. The aim was to analyse the impact of RT induced primary testicular failure on severe 
postoperative adverse events (AE, Clavien-Dindo grade 3+) in men treated for RC. 104 men were 
included from the previous cohort study. T and LH were sampled at baseline and after RT. The 
association between of primary testicular failure and severe postoperative AE was analysed using 
longitudinal regression. 25% had severe postoperative AE (AE+). Baseline data did not differ 
significantly between groups. The AE+ group had comparably higher LH/T-ratio after RT. 0.603 
(0.2-2.5) vs 0.452 (0.127-5.926, p=0.035). The longitudinal regression analysis found that 
preoperative change in T (OR 0.844, 95% CI 0.720-0.990, p=0.034), LH/T-ratio (OR 2.020, 95% CI 
1.010-4.039, p=0.047) and low T (<8 nmol/L, OR 2.605, 95 CI 0.951-7.139, p=0.063) were 
associated to severe postoperative AE. Preoperative RT induced decline in T seems to be a risk factor 
for severe postoperative AE in men with RC. 
Paper IV. Sarcopenic signs have been related to worse cancer specific survival and the skeletal 
muscles in men are sensitive to T. The effect of RT induced testicular failure may therefore be of 
importance in men treated for RC. Based on the cohort study in Paper II, 102 men with RC were 
included. Using CT or MRI scans from routine examinations at baseline and one year after surgery, 
skeletal muscle (SM) area at 3rd lumbar vertebra was measured. Testicular function was evaluated by 
measurement of serum T and LH. The association between change in T (and calculated free T) and 
SM as well as systemic cancer recurrence and SM were analyzed. Change in free T level is associated 
with change in psoas major area (p=0.005) and abdominal muscle area (p<0.001). Systemic cancer 
recurrence was associated with changes in total SM area (-5.96 (-10.7 - -1.24) cm2, p=0.013) 
 
In conclusion, Abdominal and pelvic muscles are as androgen sensitive as appendicular muscles, and 
impaired testicular endocrine function due to RT impacts muscle area. Preoperative decrease in T 
increase risk of severe postoperative AE. Elevated LH and decreased muscle area are associated with 
systemic cancer disease. 
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 BACKGROUND│1 
Background 
Rectal cancer epidemiology 
Rectal cancer (RC) was diagnosed in 2,145 people in Sweden 2016 and is thereby the 8th most 
common cancer, see Figure 1.1, 2 Men are more likely to suffer RC than women, with an age-
standardized incidence of approximately 26 versus 17 per 100,000 residents in Sweden, Figure 2.1 
Standardized for age, RC mortality has been stable the last decade, see Figure 3. 
 
 
Figure 1. New cases of Rectal cancer in Sweden per year.  
Source: The Swedish Cancer Registry, The National Board of Health and Welfare. 
 
 
Figure 2. Age-standardized Rectal cancer incidence, per 100,000 persons in Sweden.  
Source: The Swedish Cancer Registry, The National Board of Health and Welfare. 
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2│BACKGROUND  
 
Figure 3. Age-standardized mortality rate due to Rectal cancer, per 100,000 persons in Sweden.  
Source: The Swedish Cause of Death Registry, The National Board of Health and Welfare. 
Worldwide, the incidence rate of RC differs between countries with generally higher rates in the 
more economically developed ones, illustrated in Figure 4. 
 
Figure 4. Estimated age-standardized incidence rates in 2018, rectal cancer, in both sexes of all ages. Source: GLOBECAN 3 
Risk factors for rectal cancer 
As illustrated in Figure 4, the incidence rates of rectal cancer differ between regions, which is 
attributed to life-style factors including demographics, diet and physical activity. Differences in 
access to medical care and incomplete national registers may be a factor too. Indeed, it’s been 
shown changes towards a more western life-style induce “western” incidence rates for cancer, e.g. 
migrants within few generations share the incidence rates of cancer of their new country.4 
Increasing age, smoking and high body mass index (BMI) is known risk factors for rectal cancer.5, 
6  
Dietary risk factors for rectal cancer are less clear than for colon cancer and fever specific studies 
have been conducted.7 In a large meta-analysis, including 111 prospective studies, Vieira et. al 
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found a borderline association between processed meats and rectal cancer (Relative risk (RR): 1.08 
for 50g/day increment, 95% CI =1.00–1.18, p= 0.77), a stronger one with alcohol (RR: 1.08 per 
10g/day increment (95% CI = 1.07–1.10, p=0.54).7 The Malmö Diet and Cancer Study found that, 
in men, high intake of beef has been related with increased risk of RC while intake of fish had an 
inverse relationship with RC risk in both sexes.8 Comparison between non-drinkers versus drinkers 
of alcohol in a smaller meta-analysis yielded a RR 1.42 (95% CI 1.03–1.96).9 The majority of studies 
report a combined risk of colorectal cancer (CRC), usually not stratified for adenocarcinoma of 
the colon and rectum separately. Red and processed meat and alcohol are generally accepted risk 
factors, however, vegetarians seem to have the same mortality from CRC as non-vegetarians.7, 10, 11 
High intake of beef was associated with less risk of colon cancer in women (men had a similar 
trend) while pork increased the risk in the Malmö Diet and Cancer Study.8 Protective effects 
regarding CRC are attributed to whole grains, vegetables, dairy and fish.7 The dietary factors in RC, 
colon cancer and, above all, the combined CRC, seems to be depending on sex, meat source and 
tumor location in the intestine, which could explain the sometimes conflicting results in different 
studies. The reason might be different embryological origins of the large intestine, dictating the 
local cell structure and function.12 
 
Colorectal cancer risk is increased in persons suffering inflammatory bowel disease such as Crohn’s 
disease (CD) and ulcerative colitis (UC).13, 14 The risk of CRC increases even more if debuting at 
childhood (CD: Hazard ratio (HR) 5.8 (3.2 to 10.4), UC: HR 33.3 (23.1 to 49.1).15 For rectal cancer 
specifically, UC but not CD, is a risk factor: IRR 1.84 (95% CI, 1.27-2.58) - 1.90 (95% CI, 1.05-
3.43).13, 14 
 
Oral antibiotic use is implicated in colon cancer risk, but seems protective regarding RC, findings 
recently verified in a large matched case-control study concluding that there was a dose-dependent 
risk increase in the proximal colon (p<0.001), especially regarding anti-anaerobic antibiotics.16 A 
negative association was found between antibiotic use and RC (p=0.003), particularly if use 
exceeded 60 days. The association was detected with antibiotic use more than ten years prior to 
cancer diagnosis (OR=1.17 (1.06 to 1.31)).  
Heredity  
Heredity is an important factor in CRC, and has been linked to 2-8% of all CRCs.17 Having a first-
degree relative with CRC induces a RR of suffering CRC of 2.24 (95% CI 2.06 to 2.43), and having 
two or more increases the RR to 3.97 (95% CI 2.60 to 6.06).18 Hereditary syndromes also induce 
high risk contribution to approximately 5% of all CRCs. These cancer syndromes are usually 
separated into polyposis or non-polyposis syndromes.  The non-polyposis Lynch syndrome is the 
most common syndrome, resulting in CRC risk of 43% at a median age of 47 in women, and 66% 
at a median age of 42 in men.19 Familiar adenomatous polyposis (FAP) is the second most common 
syndrome overall, with penetration approaching 100% at 40 years of age if inherited 
(approximately 30% are de-novo mutations).17, 20
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Anatomy of the rectum 
The gastrointestinal tract (GI) runs from the mouth to the anus and is derived from endoderm. 
The primitive gut evolves into three different parts, foregut, midgut and hindgut. The foregut gives 
rise to the tract from esophagus to the upper duodenum and the part from the suspensory muscle 
of the duodenum up to the last third of the transverse colon stems from the midgut. The last third 
of the transverse colon to the upper part of the anal canal is stems from the hindgut and, when 
fully evolved, ends at the linea pectinate, marking the junction from columnar glandular epithelium 
of the rectum to the squamous epithelial cell of the anus. The areas with different embryological 
origins have differing arterial supply. Structures evolved from the foregut are supplied by the celiac 
trunk and midgut structures rely on branches from the superior mesenteric artery. The rectum, 
evolved from the hindgut, is supplied by the superior rectal artery, originating from the inferior 
mesenteric artery. The inferior rectal artery originating from the internal iliac arteries and, with 
individual variation, the middle rectal artery supplies the most distal part of the rectum. The 
differing embryological origins probably explain the differencing characteristics of the proximal 
colon and the distal part of the GI. The rectal mucosa produces a more acidic mucin compared to 
proximal colon, which in turn has a more extensive capillary network suggested to be important 
in water re-absorption.12 
 
The rectum is located in the pelvis with the upper third anteriorly and laterally covered by 
peritoneum viscerale, the middle third only covered anteriorly and the last part is inferior to the 
peritoneum parietale. Between the rectum and the prostate in men and the vaginal wall in women 
the rectoprostatic fascia or rectovaginal fascia (Denonvillier), respectively, with unclear embryonic 
origin, is located. The rectum is supported by the pelvic diaphragm and musculus levator ani and 
the arterial, venous and lymphatic vessels and tissue sustaining it is contained in a fatty structure 
termed the mesorectum by Prof. Heald in 1982.21  
Definition of Rectal cancer 
Rectal cancer is defined by the Swedish national care program for CRC (SNCP-CRC) and in the 
guidelines from the European Society of Medical Oncology (ESMO), as adenocarcinoma with 
distal tumor border located within in the last 15cm of the large intestine, measured from the anal 
verge with rigid rectoscopy.22, 23 This definition is not universally used and the measured distance 
in definition of rectal cancer varies. The 15cm definition, as other general values, is arbitrary and 
real rectal length is dependent on patient characteristics, such as sex, height and weight.24 This 
might lead to misclassification of tumor location and thus impact treatment. Magnetic resonance 
imaging (MRI) has been mentioned as an alternative instrument to determine tumor location but 
anatomical landmarks need to be standardized.24, 25 
Symptoms of rectal cancer 
Rectal cancer symptoms can be local, such as change of stool habits/urgency, blood or mucus in 
the stool or a sensation of not being able to empty the bowel. Pain is relatively unusual but may 
herald a locally advanced tumor infiltrating other tissues. A tumor obstructing the lumen of the 
intestine may result in symptoms of congestion. General symptoms, such as fatigue, anemia, loss 
of weight may herald systemic disease where the rectal cancer has seeded metastases to other 
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organs. Synchronous distant metastases are present in approximately a quarter of persons 
diagnosed with rectal cancer.26  
Workup 
At presentation of symptoms a digital rectal palpation followed by rigid rectoscopy, including 
measurement of tumor distance from anal verge, shall be done.23 The tumor is described according 
to distance from anal verge, “low” < 5 cm, >5-10cm “middle” and >10-15 cm “high”.22 
Colonoscopy is recommended to detect synchronous lesions, as well as for taking biopsies for 
histopathological classification. Most rectal cancers are adenocarcinomas but there are instances 
of neuroendocrine tumors, sarcomas, lymphomas, melanomas as well as metastases from other 
primary cancers.27 Computed tomography (CT) colonoscopy may be used as a second alternative. 
In order to detect metastatic disease, CT thorax and abdomen is performed and, in RC, MRI of 
the lower pelvic area is important to investigate the extent of the tumor. In the case of a locally 
advanced tumor or distant metastasis, where the curative potential may be threatened, a positron 
emission tomography with fluorodeoxyglucose integrated with computed tomography (FDG-
PET/CT) is performed.23 Use of FDG-PET/CT increased in Sweden during the last years. 
Staging  
Usually the TNM classification system is used to describe the characteristics of RC. “T” describes 
the invasion of the primary tumor, “N” the regional lymph node status and “M” eventual 
metastatic disease, see Table 1.28 Staging is done both preoperatively, clinical staging denoted with 
the letter “c” in front of the TNM classification, and postoperatively from pathological evaluation 
of surgical specimens with the prefix “p” with an added “y” if neoadjuvant treatment was used. 
Currently the 7th edition of the TNM-classification is recommended in the SNCP-CRC but 8th 
edition, with minor differences, has been in place since late 2016.28 Some important notions are 
that in 8th carcinoma in situ is termed intramucosal adenocarcinoma, less than 20 isolated tumor 
cells are N0 and micrometastases, clusters of more than 20 tumor cells or metastases measuring 
more than 0.2 mm but less than 2 mm in diameter, are denoted N1, see Table 1.29  
Multidisciplinary team conference 
Multidisciplinary team conferences (MDT) are mandatory in Sweden in regards to RC, according 
to the SNCP-CRC, and a case be addressed at several MDTs if needed during the course of 
treatment.23 The MDT involves the specialties that are needed for its purpose: an evidence based 
best-of-care approach to RC treatment, and includes colorectal surgeons, radiologists, oncologists, 
pathologists and specialized nurses. If needed, a patient can be discussed at several stages of its 
treatment to assure best possible treatment. 
 
The MDT recommends treatment regimens, including neoadjuvant treatment, according to criteria 
regarding perceived risk of local recurrence (LR) or systemic recurrence. A popular stratification is 
the good, the bad or the ugly, representing “early”, “intermediate” or “advanced” local disease 
respectively.30 This stratification has been used and modified for two decennia in Sweden. Recently, 
new ESMO-guidelines introduced five groups for a more tailored treatment.22 
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Table 1 TNM-classification of colorectal cancers, 8th edition. 
T - Tumor     
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ, intramucosal carcinoma (involvement of lamina propria with no 
extension through muscularis mucosae) 
T1 Tumor invades submucosa 
T2 tumor invades muscularis propria 
T3 Tumor invades trough the muscularis propria into the pericolorectal tissues  
T3a Minimal invasion: <1mm beyond the borders of the muscularis propria  
T3b Slight invasion: 1-5 mm beyond the of the muscularis propria  
T3c Moderate invasion: >5-15 mm beyond the borders of the muscularis propria  
T3d Extensive invasion: >15 mm beyond the borders of the muscularis propria 
T4 Tumor penetrates the visceral peritoneum and/or directly invades other organs or 
structures  
T4a Tumor penetrates to the surface of the visceral peritoneum  
T4b Tumor directly invades or is adherent to other organs or structures 
N - Lymph nodes   
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph nodes  
N1a Metastasis in 1 regional lymph node  
N1b Metastasis in 2-3 regional lymph nodes  
N1c Tumor deposit(s) in the subserosa, mesentery or nonperitonealized pericolic 
or perirectal tissues without regional nodal metastasis 
N2 Metastasis in ≥4 regional lymph nodes  
N2a Metastasis in 4-6 regional lymph nodes  
N2b Metastasis in ≥7 regional lymph nodes 
M - Metastasis   
MX Distant metastasis cannot be assessed 
M0 No distant metastasis  
M1 Distant metastasis   
M1a Metastasis confined to one organ or site  
M1b Metastasis in more than one organ/site or peritoneum 
Adapted from Amin et al.28   
Radiotherapy 
The effects of irradiation were first hinted as the research into the field of x-rays intensified in end 
of 19th century and dawn of the 20th. The irradiation caused cutaneous burns, and in analogue to 
other treatment modalities, radiation was used to treat skin diseases, including epithelioma and 
basal cell carcinoma, as well as benign outgrowths. The use of radiotherapy (RT) and, little later, 
radium was booming and subject to strong publication bias. However, evidence of adverse effects 
was piling up and the need to curb the, sometimes rampant, use of irradiation was acknowledged. 
In the 1920s Henri Coutard, building on the findings of Claudius Regaud, both working at the 
Curie Institute, presented data showing that fractioning RT had better effect with less adverse 
effects. In the early 1930ies, Coutard had refined a model with fractionated RT that is the basis of 
current RT.31 
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The two main objectives of preoperative RT in RC treatment are to decrease the tumor size and 
sterilize the excision margins. The decrease in size caused by RT is due to cancer cell death from; 
necrosis, uncontrolled death with highly inflammatory environment; apoptosis, controlled cell 
death with little or no inflammation; failed cell division at mitosis, mitotic catastrophe. Irradiation 
damages cells by various pathways, including directly destroying chemical bonds in 
molecules/proteins or by creating free oxygen radicals that in turn damage chemical bonds, both 
may disrupt cell membrane integrity, initiate apoptosis or induce DNA damage that will prevent 
proper mitosis. The radiation dose absorbed by the targeted tissue, joules per kg, is measured in 
Gray (Gy). Radiotherapy induces differing effects in different tissues and cancer types depending 
on their characteristics. Tissues with high cell proliferation, such as cancers in general, are more 
susceptible to damage as the effect of RT peaks at mitosis. Sterilization of the excision margin aims 
at removing undetected cancer cells outside of the main cancer mass in order to minimize the risk 
of LR. In order to achieve these objectives, the target volume of RT comprise the primary tumor 
and a safety margin, as well as regional lymphatic tissue. Fractioning RT allow for a differentiation 
between normal tissue and the tumor trough what is known as the four R´s: Repair of damage in 
normal and cancer cells, Reoxygenation of the cancer, Redistribution trough the cell cycle toward 
mitosis, and Regeneration of cells between fractions.32 The mostly used RT regimens in Sweden 
today are both preoperative and consists of either 5 x 5 Gy “short course” (sRT) or 28 x 1.8 Gy 
with concomitant chemotherapy, “long course” or chemoradiotherapy (CRT).   
Effect of Radiotherapy in Rectal Cancer treatment 
The Stockholm Colorectal Cancer Study Group formed 1980 started the Stockholm I trial to 
elucidate the effect of RT in RC treatment. The study compared traditional surgery versus 
traditional surgery with preoperative sRT.33 The trial found that sRT cut the local cancer recurrence 
risk in half, from 30 to 15%, but quadrupled the risk of postoperative complications and mortality 
from 2% to 8%.33 The increased postoperative mortality was primarily driven by cardiovascular 
death in study participants older than 75, and the findings were incorporated in the next trial. 
Stockholm II trial included younger patients, used an evolved RT technique and the trial could 
repeat the relative risk reduction of 50% in RC recurrence but this time without increased mortality 
risk.34 The study concluded that RT should be an alternative in RC treatment but age and 
cardiovascular co-morbidity must be considered at an individual level when recommending RT. 
The Swedish Rectal Cancer Trial found similar results regarding local recurrence and, additionally, 
a benefit in overall survival (HR: 0.79, 95% CI 0.66-0.92) and cancer-specific survival (HR: 0.69, 
95% CI 0.55-0.83), findings that were deemed trustworthy in a follow-up study.35, 36 In the Dutch 
Total Mesorectal Excision (TME) -trial modern surgical technique was used as baseline and study 
participants randomized to no RT or preoperative sRT and surgery within one week.37 The TME-
trial found that even if LR in general was lower with TME technique compared to traditional 
surgery, sRT more than halved cumulative LR risk after ten years follow-up (from 5% to 11%).37 
Several studies, the Uppsala Trial among them, have found that preoperative RT seems preferable 
to post-operative RT in regards to LR, even if the latter minimizes the risk for unnecessary 
treatment.38-40 Chemotherapy in CRT is a sensitizing agent, i.e. it makes the tumor cells more 
susceptible to RT. The use of full-dose chemotherapy after sRT is increasing, under the LARCTus-
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study protocol (clinical trials no.: NCT03729687), based on the RAPIDO trial which had not been 
reported yet.41  
Timing of Radiotherapy and Surgery 
The timing of surgery, to operate directly after RT treatment or to delay surgery, have been up to 
debate. A delay between RT and surgery is that it allows for tumor downstaging/regression, 
sometimes to complete tumor regression, which is linked to improved survival.42, 43 The possibility 
of complete tumor regression has been mostly attested to CRT, where the concomitant 
chemotherapy is attributed to a large part of the effect and in one study increasing the possibility 
for pathological complete response (pCR, from histopathological analysis of resected specimens) 
from 7% to 16%, p=0.04.44-46 In sRT, tumor regression and even pCR has been observed if surgery 
is delayed more than 3 weeks, and in the Stockholm III trial sRT with delay had the highest 
frequency of pCR (10.4% vs 2.2% in CRT).47-52 An optimal delay has not been found, studies 
comparing six to 12 weeks delay, and nine to 14 weeks delay, both found the longer delay 
beneficiary in regards to tumor regression.53, 54 To the contrary, the GRECCAR-6 trial found no 
statistical difference between seven weeks and 11 weeks delay in regards to pCR.55 
 
In analogy to organ preservation in anal cancer treatment, Prof Angelita Habr-Gama from Sao 
Paulo started to await with surgical resection in patients with clinical and radiological signs of 
complete tumor regression.56 This selected group of patients is followed closely to detect cancer 
regrowth as soon as possible, a regimen termed “Watch-and-Wait”. Estimates of local regrowth 
range between 21-25% and the possibility to surgical salvage in case of regrowth range from 90% 
to 93% in current literature. Due to differing study designs, a solid meta-analysis has been difficult 
to produce. Compiled data of 15 studies in 2017 shows an pooled overall survival of 92% after 23-
68 months.57  More recently, a systematic review and meta-analysis including nine studies reported 
surgical salvage in 10.5% of the 248 patients treated according to Watch-and-Wait, with a relative 
risk of overall mortality of 2.42 (95% CI 0.96-6.13) and cancer specific mortality 2.63 (95% CI 
0.81-8.53) compared to traditional treatment.58 A problematic facet of Wait-and-Watch is the 
patients whose tumors doesn’t regress as they wait will have their surgery delayed without apparent 
benefit. Factors predicting a possible complete clinical response due to RT includes: lower tumor 
grade, lower cT and cN stage, higher radiation dose, and an interval of more than 6–8 weeks 
between RT and surgery.59 Currently, data is compiled in the International Watch-and-Wait 
database for further evaluation. 
 
Delaying surgery seems also beneficial regarding risk of postoperative complications. The 
Stockholm III trial recently concluded that delaying surgery 4-8 weeks after sRT compared to 
surgery within one week significantly decreased postoperative complications (OR 0.61, 95%CI 
0.45-0.83).60 
Radiotherapy recommendations and procedure 
Radiotherapy in Sweden is administered the prone or supine position and in accordance to the 
MDT, general guidelines are shown in Table 2. A suprapubic reference point is tattooed and used 
throughout the planning and administration of the RT. Dose planning and target volume (TV) are 
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made using a dose-planning CT (dpCT) or MR, covering the volume between the 4th lumbar 
vertebrae and distal to the anus. The MRI information from workup complement the dpCT. The 
volumes of interest are: Gross Target Volume (GTV), Clinical Target Volume (CTV) and Planned 
Target Volume (PTV). 
 
Table 2 Rectal cancer, neoadjuvant treatment. 
 
              
Tumor distance from 
anal verge 
T1-T2 T3a-b T3c-d T4a T4b N1 N2 mrf+ Lat. lgl EMVI 
-High, 10-15cm 0 0 5x5 5x5 5x5/CRT 0 5x5 CRT CRT 5x5 
-Middle, 5-10cm 0 5x5 5x5 5x5 5x5/CRT 5x5 5x5 CRT CRT 5x5 
-Low, 0-5cm 5x5 5x5 5x5 - 5x5/CRT 5x5 5x5 CRT CRT 5x5 
  
         
  
Notes: T = Tumor stage. N = Lymph node stage. (See Table 1) mrf+ = mesorectal fascia engaged 
(<1mm margin). Lat. lgl = Pathological lymph nodes outside mrf. EMVI = Extramural vascular 
invasion. 5x5 = Radiotherapy 25 Gy in five fractions. CRT = Chemoradiotherapy, 50.4 Gy in 28 
fractions with concomitant chemotherapy. Adapted from the Swedish national care program for 
Colorectal Cancer.23 
 
When including regional lymph nodes, CTV is denoted CTVN. The Clinical Target Volume 
includes the primary tumor and a 1-2 cm margin within the mesorectum, the primary and the 
closest secondary lymph nodes. The Planned Target Volume incorporates CTVN and adds a 
margin of 0.8cm to 1.3 cm, the latter on the ventral side and (denote PTVN. During planning, 
GTV is adjusted according to the stage of the tumor, with ugly tumors having expanded volume 
covering structures related to tumor overgrowths. Currently, organs at risk are not defined in sRT, 
but in CRT the bowel bag, bladder, pelvic bones and genitals are designated.  
Surgery  
Surgical intervention in rectal cancer historically had poor outcomes.61 The complex area of the 
pelvis is difficult to operate in and, prior to the 1980ies, blunt dissection technique was standard, 
with high risk of massive bleeding and associated with high morbidity and mortality. 
Postoperatively, autonomic nerve damage was common with adverse impact on urinary-, sexual- 
and bowel functions. Blunt dissection often failed to completely remove tumor and which led to 
a high LR, and, compounded by the inability to remove regional lymph nodes increasing risk for 
systemic disease, resulted in a high rectal cancer mortality. 
Abdominoperineal excision 
At the beginning of the 20th century, Sir Willian Ernest Miles, from The Cancer Hospital in London 
and Gordon Hospital for Diseases of the Rectum, UK, found that in rectal cancer surgery the 
volume of possible outward spread of the tumour must be excised. This in effect means the pelvic 
colon, the pelvic mesocolon and iliac lymph nodes combined with a wide perineal excision. At the 
time, this was done bluntly and the postoperative mortality was 42% which was deemed acceptable 
as the most likely alternative was recurrent cancer and death.62 With his new approach, Sir Miles 
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could decrease the frequency of LR from 95% to 30% and the procedure, abdominoperineal 
excision (APE) became the standard procedure until the introduction and spread of AR. 
Total Mesorectal Excision 
After introduction of the TME surgical technique, published in 1982 by prof. Bill Heald from the 
Basingstoke District Hospital, UK, local recurrence dropped from 30-40% to 5-10 %.61, 63, 64 Total 
Mesorectal Excision infers visually controlled sharp dissection along embryologically defined 
planes, with the aim to remove the rectum and mesorectum, including blood vessels and lymphatic 
structures, en bloc, i.e. as a intact specimen.21  By doing so, previously common adverse surgical 
complications, such as massive bleeding, nerve damages and local recurrence can be reduced 
substantially.61, 64  
 
Currently, and still based on TME, the anterior resection (AR) is the standard procedure in rectal 
cancer surgery in regards to tumors situated in the upper or middle rectum, without engagement 
of skeletal muscle of the pelvic floor or external anal sphincter. Relative contraindications are 
diminished preoperative sphincter function and fecal incontinence and severe co-morbidity. Low 
tumors often engage skeletal muscle and are thus treated by APE. The inherent risk with an 
anastomosis is anastomotic leakage (AL), a postoperative complication with comparatively high 
morbidity and mortality. In order to mitigate the risk of AL a proximal, temporary, stoma is often 
created.65 If an anastomosis is not deemed a viable alternative, usually dependent on poor physical 
status in the patient or emergency, Hartmann´s procedure or intersphincteric APE with an 
colostomy may be performed.66-68 
APE evolved 
With the introduction of the TME technique the pronounced improvements regarding LR did not 
really translate to the full extent in APE.69 At that time, APE was performed according to TME 
standards in the abdominal segment but the perineal approach was done in part bluntly due to bad 
visibility. There were several problems with perineal part, one being that the procedure starts close 
to the externals sphincter and follows the perianal muscles towards the pelvic floor to meet up the 
abdominal part resulting in a waist at that location where there is a risk of compromised 
circumferential resection margin (CRM), compounded by the bad visibility. Another problem was 
that there was no clear standardization of the procedure making comparisons and refinement 
difficult. 
 
To address the relative worse outcomes in APE compared to AR, the extralevator APE (ELAPE) 
technique was developed by Professor Torbjörn Holm, from the Karolinska University Hospital 
in Stockholm. In ELAPE the abdominal dissection is terminated before the pelvic floor at the top 
of the levator ani muscle and the perineal dissection is done outside the external sphincter, along 
the levator ani fascia up to its origin where it meets the abdominal dissection. This results in a 
tubular specimen without a waist. Observational studies confirm a better outcome regarding CRM 
and perforations.70-72 Several meta-analyses have been conducted with differing results, one 
including 949 patients found that ELAPE had less perforations, less positive CRM rate and less 
LR compared to APE.73 Another, larger, found no benefits regarding CRM or LR, but confirmed 
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significantly less perforations in ELAPE compared to conventional APE.74A A recent multicenter 
study did find significant benefits of ELAPE in overall, disease free and local recurrence free 
survival, particularly in advanced tumors.75 
 
Intersphincteric APE is another variant, suitable when a low anastomosis is unfavorable. The 
perineal dissection is done between the internal and external sphincter and along the proximal 
surface of the levator ani and meets the abdominal part at the level of the puborectal muscle. In 
locally advanced cancer, if including levator muscles, ischioanal fat and/or perianal skin, or in the 
case of perforated cancer with abscess or fistulation in the ischioanal compartment, ischioanal APE 
is indicated. Ischioanal APE includes the levator ani muscle, the ischioanal fat (including a perianal 
fistula if present) and, if skin involvement, a wide skin excision.69  
Laparoscopic surgery 
Minimal invasive techniques, i.e. standard or robot-assisted laparoscopic surgery, are gaining 
ground and are currently applied in Sweden approximately 50% of rectal cancer patients. About 
40 % of the laparoscopic surgeries are robot-assisted, an increasing trend.76 
Minimal invasive surgery benefits, in relation to open surgery, include decreased time to recovery 
and length of hospital stay and quicker return of bowel function.77, 78 The drawback of laparoscopic 
surgery is longer operating time and non-inferiority when compared to open surgery could not be 
established in T1-T3 rectal tumours in the ALaCaRT trial or the ACOSOG Z6051 trial including 
stage II-III rectal cancers, risk difference of -7.0% (95% CI, -12.4 - ∞) and -5.3% (95% CI, -10.8% 
- ∞) respectively.79, 80 
 
A novel technique is transanal TME (taTME), laparoscopic abdominal surgery combined with 
transanal access to perform a bottom up TME trough a natural orifice. A systematic review and 
meta-analysis found favourable outcomes regarding positive CRM (OR = 0.39, 95% CI = 0.17–
0.86), operating time (weighted mean difference = -23.45, 95% CI = -37.43 to -9.46) and overall 
postoperative complications (OR = 0.65, 95% CI = 0.45-0.95). 81 Given that the methodology of 
taTME is relatively new, more prospective studies are needed. 
Local excision 
In early stage cancers, such as Tis, or even in cases with cancers that have regressed enough from 
neoadjuvant treatment, local excision may be an alternative to organ preservations and thereby 
minimize treatment-related adverse functional outcomes.82, 83 Local excision may be performed 
transanally with techniques allowing for direct visual control, with transanal endoscopic 
microsurgery (TEM), or with transanal minimal invasive surgery (TAMIS) using laparoscopic 
instruments. The benefits of local excision are less morbidity and earlier hospital discharge but the 
draw-back is increased risk of LR, with the more advanced TEM or TAMIS having a lower risk 
for LR than transanal excision.84 Patient selection is of importance and in addition to MRI, 
endoscopic ultrasound should be used for correct assessment of T-stage.  
12│BACKGROUND  
Current results of rectal cancer treatment in Sweden 
In Sweden the average risk of LR is below 3% after three years in regards to tumours classified as 
T1-T3 M0, with or without RT, and 6% for T4.76 After five years the total LR risk is below 5%, 
but the coverage ratio is less than for the 3-year follow up, decreasing the possibility to draw 
conclusions from the material.76 The relative three-year survival (any death), in all patients without 
metastases is 87%, and 94% in patients having a resection.76 The stadium of rectal cancer have a 
large impact on survival, in patients with stadium I disease the relative five-year survival was 0.95 
while for IV disease its 0.2. 
Adverse effects and postoperative complications 
The treatment for rectal cancer, both RT and surgery, also incurs adverse effects and the risk of 
potential complications as well as purely structural changes, e.g. removal of the rectum and its 
niche in the bowel function.  
Functional loss 
By removing the rectum and distal colon to a varying degree infers loss of their inherent functions: 
the ampulla recti store feces until stretch sensors in the rectal wall triggers the urge to defecate and 
the distal part of the colon, colon descendens and colon sigmoideum, reabsorbs water and helps 
in feces storage. In sphincter-preserving surgery, low anterior resections syndrome (LARS), 
characterized by urgency, frequent bowel movements and sporadic fecal incontinence, is not 
uncommon.85 Risk- and severity factors for LARS are low remaining rectal volume, end-to-end 
anastomosis, AL, inflammation, neoadjuvant RT, female sex and age over 65 years.86, 87 The 
symptoms are usually worse just after surgery and decreases during the first year until stabilizing. 
In surgery including the sphincter, the resulting permanent stoma may lead to negative body image 
impacting physical and social functioning as well as stoma-related morbidity.85 
Radiotherapy toxicity 
Radiotherapy treatment may infer short-term, or acute, as well as long-term adverse effects.88 The 
symptoms of RT toxicity depend on effected organs, those included in the radiated volume, PTV, 
as well as those exposed to indirect or scattered radiation. Adverse effects presenting during RT, 
or within three months of RT, e.g. mucositis, are labelled short-term adverse effects and usually 
resolve within weeks to months. After the first three months the long-term effects, e.g. fibrosis, 
may be detected. 
 
In rectal cancer, acute toxicity is more often present in CRT than sRT, chemotherapy being a 
known risk factor for mucositis for example.89 The Stockholm III trial found that 7% of the study 
participants having sRT with delay developed acute toxicity symptoms requiring hospitalisation 
prior to surgery, compared to less than 1% in the group treated with sRT without delayed surgery, 
probably due to the fact they were admitted for surgery at the time (OR 24.7, 95%CI 3.3-183.7).60 
Urinary dysfunction, such as increased frequency and urgency, are more frequent in patients treated 
with RT.90 
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Long-term adverse effects of RT in rectal cancer are added onto the present surgical adverse 
impacts, compounding the symptoms. Specific long-term effects of RT include pelvic or femoral 
fractures, thromboembolic disorders, bowel obstructions, bowel dysfunction presented as faecal 
incontinence, evacuation problems or urgency, and sexual dysfunction.87 Pelvic insufficiency 
fractures, presenting with chronic pelvic pain was detected in 12.2 % of 1100 patients during a 
follow up of 36 months in a Danish study.91 Sexual dysfunction in men, including erectile and 
ejaculatory problems and decreased overall sexual function have been described, echoing findings 
in irradiated prostate cancer patients.92-94 Persisting hypogonadism is potential risk after RT 
effecting the testes.95 In analogy, women suffer dyspareunia, vaginal dryness and decreased overall 
sexual dysfunction due to RT.96 Further, the ovaries may be impacted, adversely affecting fertility 
and hormonal levels resulting in reduction of sexual desire. 83,97 In the Dutch TME-trial, RT was 
linked to long-term decreased quality of life.98 
 
Studies using data from 1980ies and -90ies suggested that RT, in rectal cancer, induced secondary 
cancers (RR 1.85, 95% CI 1.23-2.78).99 This could not be verified in a large, more recent study, 
using the Swedish Colorectal Cancer Registry including over 13000 patients and covering 20 
years.100 There was decreased risk of prostate cancer. However, even as prostate cancer risk 
decreased, RT in rectal cancer treatment has been linked to gynaecological cancers, lung cancer 
and lymphoma.101-103  
Postoperative complications 
Current statistics for Sweden report 0.5% 30-day and 1.1% 90-day perioperative mortality in 2018 
for rectal cancer patients that had been operated. The low mortality makes inference to causes 
difficult, but increasing age and comorbidity increases mortality risk.76 Globally, in data analyzed 
2010, perioperative mortality in rectal cancer treatment reached 2%.104 Historically, AE have been 
reported by various means making comparisons problematic. In 2004 Clavien et. al published a 
system for reporting AE, it has since been widely adopted.105 In global data, 11% suffered an AL 
and 12% contracted a pelvic sepsis.104 Pelvic sepsis and AL greatly increases the risk of a permanent 
stoma. In a Swedish registry study, including 1442 patients treated with AR, 10% had an AL and 
65% of those ended up with a permanent stoma.106 
 
Abdominoperineal excision, and to an even larger extent ELAPE, infers perineal wound 
complications and infections, which are even more relevant if RT is used with an increase from 
15% to 30% in regards to APE.107-110 Preoperative RT increases the risk for postoperative adverse 
events (AE) in general.33, 111   
 
The COLOR II study found that rectal cancer treatment negatively impacts sexual and urinary 
function,  and while urinary symptoms usually improve within six months, sexual problems persists 
for at least two year in men.112 Sex seems to be of great importance, e.g. male sex doubles the risk 
for AL, independent of tumor level, and increases the risk of wound disruption with 50 percent.113-
116  
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Factors mitigating postoperative complications 
Smoking cessation for at least 4 weeks prior to surgery have been found to slash the risk of 
postoperative complications almost in half, a risk reduction level that has also been found in 
enhanced recovery programs (ERAS).117-120 
Androgens 
Biosynthesis 
Testosterone (T), the main androgenic hormone, is mainly produced by the Leydig cells in the 
testis in men and, to a far lesser extent, in the ovaries in women.121, 122 Additionally, in both sexes, 
the inner and middle layers of the adrenal cortex produce dehydroepiandrosterone (DHEA) and 
androstenedione, and other androgens, which in turn are converted to T and estradiol in target 
tissues. Three to ten mg of T, equaling serum T levels of 10.4 to 34.7 nmol/L, is produced every 
day by adult men after regular puberty.123 In men without Leydig cell function, by orchiectomy or 
androgen depravation therapy in prostate cancer, T levels range from below 0.69 to 1.73 nmol/L, 
highlighting the importance of the testis for T production.124 Testosterone levels for castrate 
definition is suggested to be below 0.7 nmol/L.125 
 
In the Leydig cells cholesterol, de novo synthesized inside the cells themselves using acetyl-
coenzyme A or obtained from circulating low-density lipoproteins and stored in fat vacuoles, is 
converted to T. The initial, and rate limiting, step in the synthesis of T, and all other steroid 
hormones, is the conversion of cholesterol to pregnenolone on the inside of the mitochondrial 
membrane by the enzyme cytochrome P450scc. Subsequent steps in the synthesis of T are done 
in the Leydig cells’ smooth endosomatic reticulum and in total five different enzymes are involved 
in the process. There are four different pathways in T production, the preferred in the testis is 
called 5D-synthesis pathway and where the 21 carbon pregnenolone trough progesterone, 17-a-
hydroxypregnenolone, dehydroepiandrosterone (DHEA) and androstenediol is converted to the 
19 carbon T. Testosterone, being lipophilic, passively diffuses trough the cell membrane after 
synthesis and the Leydig cells do not in general store T. The testes also produce 
dihydrotestosterone (DHT) from T, but most, 80 %, of DHT is produced in target cells. The testes 
also utilize aromatase to produce some estrone and estradiol. 
Regulation 
Testosterone production, and spermatogenesis, is regulated by the hypothalamic-pituitary-gonadal 
axis.121 Kisspeptin, a peptide hormone mainly produced in the hypothalamus, controls, in a way 
not yet completely mapped, the pulsatile release of gonadotropin-releasing hormone (GnRH).126 
Every 60-90 minutes, GnRH is released in pulses from the hypothalamus and trough the 
hypothalamic-pituitary-portal system acts on gonadotroph cells in the anterior pituitary.127 The 
gonadotroph cells produce the main gonadotropins, luteinizing hormone (LH) and follicle 
stimulating hormone (FSH). The release of LH and FSH, although pulsatile, are not on the same 
frequency: LH is released in pulses approximately eight to 14 times per 24-hours and FSH even 
fewer due to the longer half-life of circulating FSH.121 The gonadotroph cells response to GnRH-
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or GnRH analogues as for example in chemical castration, the cells will cease excretion of LH and 
FSH. There is a circadian component in the release of LH and FSH as well, with a peak in early 
morning and decreasing levels of T during the day clearly visible in younger men but absent on 
older men.128 Due to the diurnal variation, sampling of T should be done prior to 11 a.m.129 
 
The gonadotropins are released into the circulation and act on the target organ, i.e. the testis in 
men. Luteinizing hormone, by binding to specific cell surface receptors on the Leydig cell, 
increases the conversion of cholesterol to pregnenolone by stimulating synthesis and activity of 
cytochrome P450scc as well as other enzymes and proteins that involved in the synthesis of T. 
The activation of the LH-receptor also results in expedited cholesterol availability, trough different 
pathways, to cytochrome P450scc, thereby increasing the substrate for T. 
 
Follicle stimulating hormone primarily acts on Sertoli cells, the cells responsible for 
spermatogenesis. Sertoli cells and Leydig cells cross-talk and FSH, by acting on Sertoli cells does 
to some extent impact Leydig cell function. 
 
In men in general, T levels peaks at puberty, levels out and then decline with increasing age.130 This 
was verified in a large (n = 2,395) randomized longitudinal study, showing a mean serum T decline 
with 0.1 ± 0.95 nmol/L per year after the age of 40.130 The decline is exacerbated by obesity and 
age-related chronic disease.131 
Distribution 
Ninety-five percent of the circulating T is produced by the Leydig cells in the testes. Testosterone 
is hydrophobic and thus does not passage readily on its own in the circulation, indeed, only about 
2.9 percent is free (fT) or unbound in plasma according to the latest measuring/calculation 
techniques.132 Approximately 45 %  of T is tightly bound to sex hormone-binding globulin 
(SHBG), itself mainly produced in the liver. Testosterone bound to SHBG was earlier considered 
basically biologically inactive.132 New evidence has shown that allostery between SHBGs two 
binding sites for T allows for a dynamic previously unknown. Thus, the free fraction of T is not 
strictly related to serum T concentration over a wide range. New findings suggest that SHBG may 
interact with cell membranes trough an androgen-binding protein and/or be internalized in cells 
and initiate a biological action.133 Factors and conditions that increase SHBG, such as age, 
hyperthyroidism and liver disease decrease fT, but not to the extent earlier thought.132 Certain 
conditions decrease SHBG, namely obesity and diabetes, probably due to low-grade inflammation 
and increased quantities of hepatic lipids.133 About 33 to 54 % of T in circulation is compatibly 
loosely bound to albumin, the most abundant protein in the serum, and may dissociate at capillary 
level to varying degree depending on local conditions and thus, together with fT, termed 
bioavailable T.133, 134 In addition, orosomucoid and corticosteroid-binding globulin (CBG) also 
transport T but their, to date incompletely comprehended, role is believed to be less significant.133  
Currently, the main theory is still that it’s the free fraction of T that diffuses into target cells and 
binds to the androgen receptor (AR) in order to mediate its effect. In some cells, e.g. in the prostate, 
T is converted to the 30-50 times more potent DHT by the enzyme 5a-reductase. Certain target 
cells may also convert T to estradiol using aromatase. In contrast, possible target cells in peripheral 
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tissue have been found to have the capability to convert the, in circulation, more abundant DEHA 
to T or DHT, effectively increasing their possible intracellular concentrations.135 Estradiol binds to 
its specific receptor but DHT binds the AR.121 The androgen receptor is a homodimer in the family 
of nuclear receptors, T and the AR forms a complex that is a transcription factor.  
Metabolism 
Testosterone, and other androgens, are mostly and efficiently metabolized in the liver to 17-
ketosteroids. The metabolites are primarily water soluble and excreted in the urine and to a lesser 
extent in the feces. Less than two percent are deposited as T in urine.121 The half-life of fT in 
circulation is around 10 minutes. 
Effects 
The classical and widely acknowledged effect of the T-AR complex in the nucleus is increased 
transcription and production of proteins, with androgenic and/or anabolic properties.136 
Additionally, in the last few decades mounting evidence describes non-genomic signaling, with 
effect within seconds to minutes, interacting with cell membrane-bound or cytoplasmic proteins.136 
Possibly, this non-genomic effect mainly influences the classical AR, and other steroid receptors, 
genomic activity.136  
 
Androgenic and anabolic response are tissue specific and varies during development and 
adulthood.137 The androgen and estrogen receptors are widely distributed in tissue, including 
muscle, bone and the brain. Even different muscles have differing number of AR.138 Androgenic 
effects are those related to development of the male sexual characteristics and anabolic are the 
growth-promoting effects on somatic tissue.121 Mutations in the AR gene may result in varying 
grades of androgen insensitivity, ranging from infertility to having female genitals and no or little 
pubic hair.139 Another example is polymorphism in the polyglutamine (CAG) repeat sequence in 
the AR, which affects the transcription intensity of the AR, fewer CAG repeats results in stronger 
androgen effect.140 Having more repeats than 38 is associated with androgen resistance and spinal-
bulbar muscular atrophy.140 The androgenic effects are most significant during development in the 
embryo and during puberty, in adulthood its mainly maintaining the male phenotype.  
 
Anabolic effects of T traditionally include dose-dependent increase of appendicular skeletal muscle 
mass, by growth of existent muscle fibers, and muscle strength in men of all ages, as well as loss 
of adipose tissue.141-145  Additionally, bioavailable T has recently been shown in a pilot study to have 
an association with abdominal muscle area.146 The hypertrophic effect of T on muscles has been 
abused since last century in order to gain muscle mass, increase performance and endurance, lose 
fat mass and to increase masculine appearance.147 It is T, and probably not DHT, that seems to be 
the effective hormone in regards to muscle mass, as shown by Bhasin et al.148 The mechanisms 
behind the hypertrophic effect of T on muscles are not fully elucidated but evidence suggest that 
T interacts in several steps in muscle remodeling.142 Skeletal muscles are syncytium of 
multinucleated cells, fibers, surrounded by collagen matrix and linked to motor neurons. Adjacent 
to the muscle fibers are pluripotent satellite cells capable to differentiate into myoblasts, that in 
turn may fuse with the fibers in response to damage for example.142 Testosterone influences the 
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synthesis and breakdown of fibers as well as pluripotent stem cell commitment and differentiation 
into satellite cells and myoblasts.142 Further, it seems the initial number of motor neurons during 
growth and the maintenance of size is associated with T.142 Testosterone within normal levels are 
mainly seen to halt protein degradation, and are by far not sole determinant of muscle size or 
power, physical exercise is a key component to muscle hypertrophy and possibly due to intracrine 
androgen action.135, 149 As well as different muscles express different number of AR, they also react 
differently to exercise and steroid exposure.138 Low T, and especially low fT, have been associated 
to frailty, even when adjusted for possible confounders such as morbidity.150 Testosterone 
replacement therapy in older men with T in the lower half of normal ranges, a notably effect on 
muscle mass and power was found, with a difference depending administration intensity, weekly 
versus monthly, where the former had a stronger effect in type 1 or slow fibers.151  
 
There seems to be a high individual variation in optimal T levels to maintain lean mass, fat mass, 
strength, and sexual function.152 Eighty percent of the circulating estradiol in men comes from T, 
converted by aromatase, and T and estradiol levels in blood are positively correlated.153, 154 In men, 
estrogen deficiency seems to increase body fat and decrease in sexual function.152 
 
Androgen receptors are found in both osteoblasts and osteocytes and T has a large role in skeletal 
growth and homeostasis.155 Testosterone promotes bone metabolism primarily through 
conversation to estradiol in the osteoblasts.156 The conversion is critical for bone density, strength 
as well as for linear growth and closure of the epiphyses and individuals without aromatase or 
estrogen receptor deficiency will suffer osteoporosis, open epiphyses and high linear growth 
rate.157-159 For periosteal growth, there seems to be an additive effect of T and estrogens.155 
Hypogonadism 
Diagnosis of hypogonadism, defined by The Oxford Dictionary as “reduction or absence of 
hormone secretion or other physiological activity of the gonads (testes or ovaries)” has increased 
during the last years in Sweden, see figure 5. Hypogonadism occurring before puberty, if left 
untreated, results in incomplete male phenotype, with eunuchoid phenotype including abnormal 
tallness, small penis and testes, sterility, impaired development of secondary sexual characteristics 
in addition to decreased libido and sexual potency. Post-pubertal debut of hypogonadism does not 
infer differences in already developed male characteristics but adversely impacts sexual function, 
body composition and psychological components, e.g. mood and motivation. 
 
Diagnosing hypogonadism may be difficult, especially as some symptoms overlap with morbidity 
and with ageing, such as decrees in bone formation, loss of muscle mass and appetite.121 Further, 
the individual differences in optimal androgen levels means that general, and adequate, cut-offs are 
difficult to set, making symptoms even more important. Hormone levels also depends on the type 
of hypogonadism, see below.  
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Figure 5 Testicular dysfunction, E29 (ICD-10), Cases per 100,000 Swedish inhabitants.  Source: The National Board of Health 
and Welfare. 
Primary hypogonadism 
Hypogonadism, or testosterone deficiency, may be due to different pathologies. Primary 
hypogonadism is due to primary testicular failure, i.e. the testicular cells are unable to produce T 
at adequate levels and/or spermatogenesis is impaired, and results in a corresponding increase in 
LH/FSH as the hypothalamic-pituitary-gonadal axis responds. Primary hypogonadism is seen in 
Klinefelter’s syndrome, testicular tumors, mumps-related orchitis, testicular irradiation, 
chemotherapy and testicular trauma.123 Primary hypogonadism often presents with sexual 
symptoms, such as decreased libido, decreased frequency of morning erections and erectile 
dysfunction.160, 161 Table 3 includes other symptoms associated with hypogonadism. Serum T levels 
below 8 nmol/L are considered likely hypogonadal, while levels between 8 nmol/L and 12 nmol/L 
may be so, if combined with symptoms and/or if fT is below 220 pmol/L.161-163 
Secondary hypogonadism 
In secondary hypogonadism, or hypogonadotropic hypogonadism, the pathology is in the 
hypothalamus or pituitary and T levels and sperm count are subnormal, but LH and FSH are 
normal or reduced. Secondary hypogonadism may be congenital such as in isolated 
hypogonadotropic hypogonadism, Kallmann syndrome or genetic conditions such as Prader-Willi 
syndrome or Laurence-Moon syndrome.123 Secondary hypogonadism may also be secondary to 
hyperprolactinemia, processes involving the pituitary (i.e. tumors; abscesses; infarcts; irradiation), 
Cushing’s syndrome, substance abuse, serious or chronic morbidity or hemochromatosis.123 
Late-onset hypogonadism 
Hypogonadism after normal puberty is labeled late-onset hypogonadism (LOH). It seems to be a 
combination of primary and secondary hypogonadism.164 In the European Male Ageing Study 
(EMAS) it is defined as serum T levels below 11 nmol/L, fT levels below 220 pmol/L combined 
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with three symptoms: (1) decreased number of morning erections, (2) erection insufficient for 
intercourse, (3) decreased sexual interest.161 
 
Late-onset hypogonadism has been associated with cardiovascular diseases, metabolic syndrome, 
diabetes etc.165-167 Thus, its it should be identified as soon as possible, to reduce risk of impaired 
quality of life and for subsequent morbidity.131, 165-167 
 
Table 3. Symptoms of hypogonadism in men 
A. More specific symptoms and signs B. Other less specific symptoms and signs 
Reduced sexual desire (libido) and activity 
Decreased spontaneous erections 
Breast discomfort, gynecomastia 
Loss of body (axillary and pubic) hair, reduced shaving 
Height loss, low trauma fracture, low bone mineral 
density 
Hot flushes, sweat 
Decreased energy, motivation, initiative, and self-
confidence 
Feeling sad or blue, depressed mood, dysthymia 
Poor concentration and memory 
Sleep disturbance, increased sleepiness 
Mild anaemia (normochromic, normocytic, in the 
female range) 
Reduced muscle bulk and strength 
Increased body fat, body mass index 
Diminished physical or work performance 
Adapted from Bhasin et al. 2010.168  
Compensated hypogonadism 
Compensated hypogonadism, more recently termed and defined as increased LH, >9.4 IU/L, with 
generally normal T, is increasingly in focus as its been related to long-term cardiovascular disease 
and increased all-cause mortality.169-172 In situations that infer chronic testicular stimulus by LH, the 
testicular reserve capacity may be overtaxed, which in turn may result in inability to cope to 
additional stress.172, 173 
Treatment for hypogonadism 
Hypogonadism may be treated with T, i.e. hormone replacement therapy (TRT), with some 
exceptions. Prostate or breast cancer, as they are responsive to T, must not be present and 
increased monitoring is advised if the individual 1st degree relatives with prostate cancer. 
Hematocrit above 53% should be investigated and treated before TRT. Congestive heart disease 
should be well medicated and in patients with cardiovascular disease, T dose should be carefully 
titrated. Reversible physiological and medical factors, e.g. obesity, glucocorticoid, spironolactone 
or ketoconazole treatment or substance abuse, that should be addressed first. Previously, TRT was 
considered able to induce prostate cancer, a notion that has been debunked.174-176 
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The effect of TRT has been studied extensively and positive effects have been noted. Lean body 
mass is increased in a wide range of study participants, in both primary and secondary 
hypogonadism as well as in LOH.177-179 Studies have also shown increase in skeletal muscle strength 
in response to TRT, but not univocally so, and also functional outcomes have been harder to 
show.175, 177, 180-182 Many older studies have been quite small, short duration and/or with differing 
outcome measurements.175 In 274 older, intermediate-frail to frail men, with serum T ≤ 12nmol/L 
or fT ≤250 pmol/L Srinvivas-Shankar et al. found TRT to increase muscle mass in all men and 
physical function in frailer or older men.183 Somatic and sexual function was increased. In 
conclusion, TRT increases muscle mass in hypogonadal men, with larger impact on those with 
lower T levels. The increase in muscle mass have not been clearly linked with increased strength 
or physical function, with conflicting results in the literature but some evidence points at effects, 
at least in older and frail patients. In regards to sexual function, TRT have been shown beneficial 
in regards to erectile dysfunction as well as in general quality of life (QoL) in patients with diabetes 
type 2.123, 184 
 
In bone metabolism, TRT decrease bone loss and increases in bone density.185-189 Snyder et al. 
found a relative increase in estimated spine trabecular bone strength, for TRT versus placebo, of 
8.5% (95% CI, 6.0% - 10.9%) in older men.187 However, the effect on fracture rate is unclear as 
present studies are too short. 
 
In addition to T in TRT, selective androgen receptor modulators (SARMs) first described in the 
1990ies may be an alternative with shown anabolic effects without androgenic effects, such as 
impact on prostate size, hair and skin.190 Currently, there is no approval for their use. 
Testosterone and Radiotherapy 
A review of testicular exposure to irradiation in RT treatment found that 3-17 % of the prescribed 
dose, 50Gy, hit the testes directly translating to a mean testicular dose (TD) ranging from 1.24 Gy 
to 8.4 Gy.191 The variation being dependent on field size, field type, tumor location, location of the 
testes at moment of RT and the type of shielding for the testes. This does not take scattered 
irradiation into account.  Radiotherapy in RC treatment have been found to decrease in T levels to 
varying degrees.191-196 Recently a dose-response association between testicular radiation and acute 
testicular failure was shown, with resulting decline in serum T.95 The exact extent of RT induced 
T decrease have been hard to quantify, varying study design and small sample size making robust 
inference difficult.  
 
One study included 25 men where only 16 submitted hormone samples at follow-up, four to six 
weeks after RT, and with a trend of increasing T levels with longer interval.193 Another, smaller 
(n=10), study showed a 78 % decrease in serum T after long-course RT.195 However, follow-up 
was conducted in different timespans, seven patients were analyzed three to eight weeks after RT 
and three were analyzed 11-12 months after RT.195 A larger (n=290) study by Bruheim et al. used 
a cross-sectional retrospective design.192 In this study, follow up time ranged from two to 12 years 
(median 3.9 years for irradiated patients and 5.5 years for non-irradiated patients). Several factors 
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differed between the studied groups, possibly impacting the results.192 Using multimodal therapy 
with curative intent, Hennies et al. showed a 60 % decrease in serum T and a 91% increase in LH 
in 68 men one year after RT.194 Chemoradiotherapy induced a mean T level decrease from 15.4 
nmol/L prior to treatment to 8.0 nmol/L after more than 4 years.197 In a sub-study including 40 
study participants of a Swedish cohort of rectal cancer patients, the mean serum T did not differ 
significantly a year after RT, but LH did (11.5 nmol/L vs 10.9 nmol/L, p = 0.16 and 4.3 ± 1.9 vs 
6.1 ± 3.1 p<0.001, respectively).146  
 
In conclusion, there is compelling evidence that (C)RT results in potentially long-lasting Leydig 
cell damage in select individuals, with adverse impact on T production and, even if T regains levels, 
it requires abnormal stimulation by gonadotrophs. 
Muscles 
Function 
Muscles generate the force needed for life. The human body uses three types of fundamentally 
different muscles: skeletal muscle, smooth muscle and cardiac muscle.121 Skeletal muscle provides 
the force required for voluntary movement, ranging from minute corrections in eye direction to 
high jumps reaching 2.45m. Skeletal muscle. i.e. the diaphragm, also provides the work necessary 
for breathing and skeletal muscles, especially in the legs, help pump the venous blood back to the 
heart. Smooth muscle regulates, without conscious control, blood vessels and airways and controls 
the function and motility in the digestive, urinary and reproductive tracts. In the heart, cardiac 
muscle indomitably pumps blood into the circulation in order to provide the body with its needs 
in oxygen, nutrients etc. 
 
Skeletal muscle, the muscle type observed in parts of this thesis, consists of special kind of 
elongated cells called muscle fiber or myofiber. Each myofiber, 10 to 100µm in diameter and up 
to 15cm long, have several nuclei located in the periphery and is enveloped by an endomysium. 198 
Aligned myofibers form bundles, fascicles, sheathed by a perimysium. Each fascicle can include 
more than 100 myofibers and are what we see as “muscle fibers” in meat. Bundles of fascicles are 
contained in a fibrous sheath, epimysium, continuous with the fascia and with the associated 
tendons.121 The myofiber have distinct nomenclature for its components: the membrane is called 
sarcolemma, the cytoplasm sarcoplasm and the mitochondria sarcosome. The “engine” in a 
myofiber, or indeed – in the muscle, is the myofibril. Each myofiber holds several hundreds of 
myofibrils, each sub-divided by Z-plates into approximately 2-3.65µm long sarcomeres. In the 
sarcomeres, thin actin filaments partly overlap and surrounds a central thick myosin II filament. 
The different fibers turn out black and white in a microscope, which originally gave skeletal muscle 
the name: “striated muscle”. 198 Myosin II, using adenosine triphosphate (ATP) as fuel, moves 
along the actin fibers in a muscle contraction, in essence constituting the cylinders of the engine 
that provides power to all muscle movement. Genetic damage in proteins associated with the 
myofibers may result in muscular dystrophy, e.g. Duchenne muscular dystrophy. 
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Myofibers are controlled by motor neurons. One motor unit consists of one neuron and several 
to well over 1000 myofibers, and average skeletal muscles are innervated by around 100 motor 
neurons.121 The cell body of somatic motor neurons reside in the anterior horn of the spinal cord, 
except for cranial nerves and are activated voluntary or by reflex. Motor neurons have split up and 
branched nerve endings so that a single neuron can cover up to one cm2 of muscle cross-sectional 
area, and motor units intermingle with each other.198  The innervation ratio is the ratio of muscle 
fibers per motor neuron, and determines the fineness of control.121 The neuromuscular junction is 
where the motor end plate of the neuron’s axon and the muscle cell synapse. A muscles action is 
initiated by neuronal release of acetylcholine, which triggers nicotinic receptors in the subsynaptic 
muscle membrane, subsequently leading to increase of calcium ion concentrations, that ultimately 
controls the interaction of myosin II and actin within the myofibers.198 Interfering or blocking the 
synaptic activation results in muscular weakness or paralysis, e.g. curare-like substances used for 
muscle relaxation in surgery or botulism caused by a toxin produced by the anaerobic soil-dwelling 
bacteria Clostridium botulinum. Smooth and cardiac muscle have no motor end plates, only one 
nucleus per cell and several other specificities for their separate unique niches. 
 
Motor units are divided into different types depending on their characteristics. Type I or slow-
twitch motor units are highly effective at sustained, moderate intensity, work load, utilizing a large 
compliment of mitochondria and effective supply of oxygen and nutrients trough a highly 
developed network of capillaries. Type II, or fast twitch, motor units are generally suited for shorter 
bursts of high load, but are sub-divided into IIa and IIb types. Type IIa does have larger capacity 
for aerobic activity, i.e. higher mitochondria content and better supply, than type IIb that are 
adapted for rapid and powerful contractions and cope well with anaerobic conditions but for a 
limited time.  
 
Fascicles are arranged differently depending on the muscle, i.e. muscle architecture. Longitudinal 
architecture, e.g. the sartorius muscle, refers to fascicles arranged parallel to each other and to the 
axis of force generation. Longitudinal architecture provides rapid shortening but results in less 
tension. In muscles with unipennate architecture have their fascicles at an angle to the axis of 
shortening, such as the soleus muscle, resulting in more but shorter myofibers producing added 
tension but at a slower speed.121 Multipennate architecture refers to muscles with fascicles in 
differing angles to the axis of shortening, allowing for multiple functions as shown in the trapezius 
ability to both elevate and depress the shoulder.  
Regulation 
In 2004, Herbst and Bhasin concluded that T promoted muscle protein anabolism, the 
differentiation of pluripotent stem cells towards myogenic lineage and away from adipogenic and 
that motor neurons increase size in response to increasing T.142 Testosterone support myogenesis 
by increasing myonuclear number, increasing protein synthesis while decreasing protein 
degradation, increasing satellite cell number as well as increasing AR in pluripotent stem cells and 
in motor neurons.142 Type I myofibers have been found to be more T sensitive than type II.142, 147 
In men, T is the main anabolic hormone in skeletal muscle homeostasis. 
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Hormonal regulation of skeletal muscle development, fiber-type and contractility incorporates 
more than T: thyroid hormone and, mainly in women, estrogen are important.199 Other factors 
such as myokines, including myostatin, are also important.200 
 
Thyroid hormones (TH), termed T3 and T4, are released by the thyroid gland to the circulation 
where >99% binds to carrier proteins. T3, accounts for approximately five percent of TH in 
circulation but, being 3-8 times as potent as T4, is probably the most important TH. T4, generally 
attributed as a plasma storage function, is in turn converted by many target organs, e.g. liver, to T3. 
Converted T3 constituted 80% of circulating T3.198 Thyroid hormones bind to both cytosolic and 
nuclear receptors similar to steroid receptors and are important in a multitude of bodily function, 
noticeably the intermediate metabolism.121, 198 In regards to muscles, typical signs of 
hypothyroidism is low heart rate, muscle weakness and conversion of type II fibers to type I.199 
Hyperthyroidism induce fast and/or irregular heart rate and also muscle weakness among other 
symptoms. In rats, induced hyperthyroidism by injection of T3, results in a reversible conversion 
of type I myofibers to type IIb, especially in females.199 The levels of  T3 are positively associated 
with ATP turnover rate and animal studies have found faster contraction- and relaxion rates in 
hyperthyroid state.199 Skeletal muscle has two types of estrogen receptors, ERα and ERβ, with 
functions similar to AR. In ERβ knockout male mice, contractile time is increased and contractile 
speed decreased. Female sex has been linked to better endurance, in humans as well, which has 
been attributed to sex hormone difference. However, estrogen is overshadowed in skeletal muscle 
function in men by T, but interestingly AR deficient male mice models show an increase in 
endurance in type I myofibers towards a level of female wild type mice.199 Myostatin, and the 
counteracting follistatin, are recognized as major factors in muscle development and maintenance. 
Myostatin acts inhibitory on muscle growth, even degenerately on muscle tissue, and follistatin in 
turn blocks myostatin’s receptor.200 They seem to react to physical exercise, where myostatin 
decrease and follistatin increase, allowing for muscle growth.201 Lack of physical exercise or disease 
may tip the scale in favor of myostatin, inducing atrophy.200 
Sarcopenia 
Sarcopenia is derived from the Greek terms σάρξ sarx, "flesh" and πενία penia, "poverty", it was 
termed by Rosenberg in the description of age-related loss of muscular function and first described 
by Evans & Campbell.202-204 The exact definition of sarcopenia has been elusive, no doubt due to 
its multifactorial and still partly unclear genesis.204 The historically vague definition might in part 
have led to the difficulties producing well defined and reproducible studies.205, 206  In 2010, The 
European Working Group on Sarcopenia in Older People published a consensus report on 
sarcopenia, recommending “the presence of both low muscle mass and low muscle function 
(strength or performance)” for the diagnosis of sarcopenia.207 In 2011 the International Working 
Group on Sarcopenia approved a similar definition: “Sarcopenia is defined as the age-associated 
loss of skeletal muscle mass and function”.208  
 
An exact definition of “low” muscle mass is still not generally set. There are proposed cut-offs set 
at muscle mass below two standard deviations of mean reference values in young healthy adults, 
7.23 kg/m2 – 7.26 kg/m2 using dual-energy x-ray absorptiometry (DXA).207, 209 The cross-sectional 
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total muscle area, measured at 3rd lumbar vertebrae (L3) on CT or MRI, corresponds to total muscle 
mass, which facilitates assessment of sarcopenia in imaging modalities widely used.210, 211 Currently, 
the golden standard for measuring muscle mass, in regards to sarcopenia, is CT or MRI, but in 
many settings, it may be too costly or impractical, and DXA is the secondary alternative.207, 212 The 
Skeletal Muscle Index (SMI), the skeletal muscle cross-sectional area at L3 divided by body height 
squared, has been proposed to assess sarcopenia and cut-off values ranging from 43.7 cm2/m2, to 
55 cm2/m2 seem to be associated with a wide range of clinical outcomes.213-215 The wide range gives 
a hint of the difficulty to set a general cut-off and different methodologies have been. Prado et al. 
for example, uses cross-sectional muscle area measurement at L3 and optimal stratification in 
regards to mortality in their definition of sarcopenic obesity, 52.4 cm2/m2, in cancer patients.216 
Psoas sarcopenia, total psoas major area at L3 < 5 cm2/m2 is another definition set by Peng et al. 
regarding hepatic resection for colorectal liver metastases.217 The variation in methodology, and 
documentation, between studies is a problem, severely hampering comparisons and the need for 
standardization is apparent.218 In a recent review including 8,895 CRC patients, only two out of 20 
included studies showed high quality. Due to differing cut-offs and study population, sarcopenia 
prevalence ranged from 15 to 60% (myosteatosis ranged from 19-78%), but were still consistently 
related to worse survival outcomes.219  
 
Longitudinal loss of muscle mass occurs naturally after the age of 40, with a 8% decrease per 
decade that increases after the age of 70 to 15% per decade.220 Hence, muscle loss on individual 
level exceeding the norm, must be of interest. Muscle strength or function seems to be a more 
accurate predictor in regards to adverse outcomes than muscle mass, thereof the combined criteria 
for sarcopenia.212 Different tests have been put forth in evaluation of physical fitness, such as the 
Short Physical Performance Battery, gait speed or stair climb power test.212  
 
Decreased androgen level is recognized as of the main elements to drive sarcopenia, and TRT has 
been tried in order to treat the condition.205, 207 As mentioned above, the results of TRT in older 
individuals in improving physical function have not been readily forthcoming, even if muscle mass 
and strength increases.221 Sarcopenia, age and male sex are have been found to be risk factors for 
poor balance performance and thereby for fall trauma.222 Abdominal muscles, “core muscles”, are 
essential for posture and balance, and thus abdominal sarcopenia impact mobility and the risk of 
fall trauma.223 Core strength, or stability, have been related to “successful performance of activities 
of daily living in old age”.223 The reports regarding T effect on abdominal muscles specifically are 
scarcer than reports regarding either appendicular muscles or lean body mass, as in reviews by 
Isadori et al. and Neto et al.224, 225 Testosterone replacement therapy does seem to increase 
paraspinal muscles area significantly in severely hypogonadal men.226 In rectal cancer patients 
treated with RT, acutely decreased bioavailable testosterone was related to decreased psoas major 
cross-sectional area.146 The relative lack of data on abdominal muscles might be due to the lower 
accessibility using conventional muscle mass and strength measurements targeting them 
specifically, e.g. DXA measures total body lean mass, and even includes abdominal organs in that 
measurement. Using available CT/MRI scans generated in routine clinical practice may be a 
practical method to enhance patient treatment and outcomes.  
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Myopenia has been proposed as an alternative term to sarcopenia, sarcopenia being difficult to 
define and often used in relation to age related muscle loss, to describe muscle wasting more related 
to clinical factors.227 In cancer, the term cancer cachexia is used to describe ongoing isolated skeletal 
muscle depletion, refractory to nutritional support, inducing progressive functional loss.228 The 
diagnosis of cancer cachexia have three individual criteria, each enough for diagnosis: weight loss 
exceeding five percent over the past six months in a non-starving state and BMI <20 or sarcopenia 
in addition to weight loss exceeding two percent.228 
Frailty 
Frailty, a general age-associated physiologic decline in reserve and function of multiple systems 
that induces vulnerability, is a term increasingly used.229 The frail state infers impaired capacity to 
handle everyday or acute stressors. Some of the proposed clinical markers for frailty: low grip 
strength, self-reported exhaustion, slow walking speed, low physical activity and/or unintentional 
weight loss, overlaps sarcopenic and/or hypogonadal symptoms.230 Having three of the five frailty 
markers are deemed enough for being considered frail. Having two markers translates to a pre-
frail stage with high risk of progress into manifest frailty. The prevalence of frailty varies between 
studies and in relation to geographic location, e.g. in a study of older community-dwelling adults 
in ten European countries the overall prevalence was 17%, but varied from 5.8% in Switzerland 
to 27% in Spain (8.6% in Sweden).231 The risk of mortality is markedly increased in frail older 
adults, Fried et al. 2001 found adjusted HR to be 2.24 (95% CI 1.51 – 3.33) for death within 3 
years compared to non-frail individuals in a large (n=5,317) US cohort.230 
Radiology 
Tomography is imaging in sections by use of a penetrating wave. The penetrating wave may be of 
differing origin. In the case of CT, tissue absorption of x-rays from a beam rotating around the 
supine body is measured and, by computer processing, reconstructed to cross-sectional images in 
2D or 3D. Computed tomography was first used clinically in 1971, by Sir Godfrey Hounsfield in 
Hayes, UK, at EMI Central Research Laboratories. The method built on the Radon transform, a 
mathematical theory invented by Johann Radon, an Austrian mathematician, in 1917. The Radon 
Transform allows reconstruction of a function from an infinite set of its projections. Hounsfield 
shared the Nobel Prize in Physiology or Medicine 1979, with Allan MacLeod Cormack who 
independently developed theories for CT. Computed tomography is excellent in assessing organs 
and bone structures.  
 
Modern Magnetic Resonance Imaging, MRI, build upon the insights and hard work of many 
contributors, e.g. the physicists Felix Bloch and Edward Mills Purcell got the Nobel Prize in 
Physics 1952 "for their development of new methods for nuclear magnetic precision 
measurements and discoveries in connection therewith". In 1977 Raymond Damadian, Larry 
Minkoff and Michael Goldsmith performed the first human MRI body scan. The first usable, 
clinical, MRI image was produced 1980 by John Mallards team at the University of Aberdeen, and 
depicted a tumor located in a patient’s chest. In 2003, the Nobel Prize in Physiology or Medicine 
was awarded to Paul Lauterbur, of the University of Illinois at Urbana–Champaign, US, and Sir 
Peter Mansfield, of the University of Nottingham, UK, for their "discoveries concerning magnetic 
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resonance imaging". It uses magnetic fields and radiofrequencies, where the magnetic field 
(primary field) is measured in Tesla (xT). Currently, the usual field strength in clinical settings 
ranges from 1.5 to 3T, approximately 50,000 times the magnetic field of earth. The magnetic field 
influences protons in the body to align to the same axis as the field. A radiofrequency pulse is then 
used to stimulate the protons to shift out of axial alignment. After the pulse, the protons realign 
and in doing so, releases the energy induced by the pulse. The speed of realignment and energy 
released depends on the tissue type which is used to compute MRI images. It excels at imaging 
soft tissue, but fat content in muscle is more complicated to elucidate.232 
CT and MRI in Body composition 
As mentioned above, CT and MRI are golden standard to assess body muscle mass, and 
additionally subcutaneous and visceral adipose mass may also be quantified. The accuracy of 
skeletal muscle measurements for both CT and MRI has been verified in cadavers.233 In CT, various 
tissues have differing attenuation in Hounsfield units (HU): skeletal muscle approximately 40 HU 
and adipose tissue has a value around -50 to -100 HU. Adipose tissue deposition in skeletal muscle, 
myosteatosis, will decrease average muscle area HU and is thus detectable on CT.234 Radiological 
imaging can be used to assess individual muscles as well. Computed tomography and MRI have 
similar accuracy, up to approximately 5% difference between methodologies, with an error 
marginal of up to 2% in skeletal muscle, 4 % for adipose tissue.211, 235 Comparing the modalities, 
CT and MRI, CT have some benefits: better spatial resolution, more accessible, faster and cheaper, 
but this comes at the cost of irradiation exposure. The exposure to irradiation has been decreased 
with better machines and protocols. Currently, an abdominal volumetric scan covering 1st to 4th 
lumbar vertebrae (L1-4) results in less radiation, around two mSv, than the average annual 
background radiation at 2.5 mSv.232  
Adipose tissue 
Previously the level of L4-5 was deemed best regarding visceral adipose tissue measurements, and 
the level used for more than two decennia.211 In the end of the 20th century, Abate et al showed 
that the best correlation of a single 10mm MRI slice to total abdominal adipose tissue was at L2-3 
in men (n=49).236  More recent studies have found that images between L2-3 to L3-4 are closer related 
to total abdominal adipose tissue and visceral adipose tissue as well as co-morbidity.237-239 In 2007 
a larger study (n=820) found that a cross-sectional MRI image at L3 can accurately estimate the 
total visceral adipose tissue volume in both sexes.240 The association of adipose tissue, both 
subcutaneous and visceral, of single slice area at L3 with respective total abdominal adipose 
volumes were confirmed in CT by Irlbeck et al.241 Using data from the Framingham Heart Study 
there, they could also find a strong association between adipose areas and cardio-metabolic risk 
factors.241 Since visceral adipose tissue is associated with metabolic risk, measurements at L3 could 
be of a high medical interest.242 However, in regards to RC, it has been observed that area 
measurements of adipose tissue on a single abdominal slice is highly dependent on intraluminal 
gas, possibly effecting estimations.146 Special MRI protocols, Dixon sequences, are used for 
quantification of fat fraction within muscles.232 
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Skeletal muscle 
Skeletal muscle at L3 have been found to relate to whole-body composition and is the level most 
commonly used.211 Shen et al. found that muscle area on a single slice at a level 5 cm above L4-5, 
i.e. approximately the L3 given vertebra and disk height, correlated best with total skeletal 
volume.243 Other studies have confirmed this, over a wide range of subjects, from healthy to 
patients suffering from diabetes or cancer, conditions known to potentially impact skeletal muscle 
mass.210, 244, 245 Reproducibility of manual analysis of CT scans, both inter-reader and intra-reader, 
in regards to body composition have been found to be reliable.211, 246 However, as mentioned above, 
standardization of skeletal muscle analysis is currently lacking.219 
Impact of body composition in rectal cancer patients 
The importance of body composition in clinical care is evident, with mounting reports of adverse 
effects of sarcopenia in regards to outcomes. In 805 CRC patients, Malietzis et al. found myopenia 
an independent prognostic factor for disease-free survival (HR: 1.53, 95% CI 1.06-2.39) and overall 
survival (HR: 1.70, 1.25-2.31).247 In the same study, myosteatosis was related to longer hospital stay 
(p=0.034), and myopenia obesity related to higher 30-day morbidity (p=0.019) and mortality 
(p<0.001). In an earlier systematic review, Malietzis et al. pointed out the heterogeneity in the 
found studies, again highlighting the need for standardization.248 However, some conclusions could 
be drawn in regards to CRC treatment: sarcopenia increases risk for developing chemotherapy 
toxicity; 30-day mortality; length of stay; complication rates as well as the need for postoperative 
rehabilitation. Sarcopenia may also result in worse disease-free survival and overall survival rates. 
Visceral obesity negatively impacted length of stay, operation time, risk of wound infection, 
complications rates, risk of anastomotic leaks and resumption of oral intake. The importance of 
body composition was highlighted by Martin et al. in a large (n=1,473) cohort of study participants 
with lung or gastrointestinal cancers using optimal stratification.249 In that cohort, high weight loss, 
low muscle index and low muscle attenuation were found to be independent prognostic factors 
for survival.  In study participants having all three factors, the median survival was 8.4 months 
(95% CI 6.5-10.3), and this regardless of BMI. In contrast, study participants lacking the three 
factors had a median survival of 28.4 months (95% CI 24.2-32.6).  
 
By using existing radiological imaging examinations, performed as part of the workup of RC, body 
composition and, in follow-ups, longitudinal changes in body composition can be analyzed. This 
without the cost of a dedicated MRI scan or, in the case of CT, additional exposure to radiation. 
The gathered information may be used to individualize and/or risk-stratify the patients in effort to 
optimize clinical care. 
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Aims of the thesis 
The general aim of this thesis was to investigate the impact of radiotherapy on testicular endocrine 
function and its possible adverse effects in men treated for rectal cancer. The motive being to 
optimize patient information, treatment and long-term quality of life. 
 
I. To analyse the testosterone sensitivity of the abdominal and pelvic skeletal musculature 
in healthy men, using state-of-the-art methodology. 
 
II. To assess long-term impact of radiotherapy on testicular function. 
 
III. To analyse the risk of severe postoperative adverse events in relation to radiotherapy 
induced testicular failure. 
 
IV. To verify testosterone sensitivity of skeletal muscle located at the 3rd lumbar vertebrae 
and the longitudinal impact of radiotherapy induced testicular failure on muscle area 
and oncological outcome. 
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Study Participants and Methods 
The Boston Project 
Original study 
The 5a-Reductase Trial, a parallel-group, double-blind, randomized placebo-controlled trial, aimed 
at elucidating if 5a- reduction of T to DHT in fat-free mass is obligatory for mediating its anabolic 
effects. Thus, the main outcome was change in fat-free mass, measured by DXA. One of the 
secondary outcomes, prostate volume, required MRI. The trial spanned from 2005 to 2010, and 
included healthy eugonadal (serum T levels between 10,40 nmol/L and 41,64 nmol/L) men aged 
18 to 50 years.  Exclusion criteria included androgen deficiency, history of prostate cancer, lower 
urinary tract symptom score greater than 20, weight >135 kg, hematocrit > 51%, prostate-specific 
antigen (PSA) >4µg/L, creatinine > 176.8 µmol/L, aspartate aminotransferase or alanine 
aminotransferase > 1.5 times the upper normal limit. Men receiving glucocorticoids, growth 
hormone, androgens, or 5a-reductase inhibitors were also excluded. Upon completion of the 
study, the participants received $1000, else they received a prorated amount depending on 
participation time.  
Ethical approval 
The 5a-Reductase Trial was approved by the Boston University and Brigham and Women’s 
Hospital institutional review boards (Protocol Numbers: H-24207 & 2013-P-000139/1). Informed 
consent was given by all study participants. The trial is registered at ClinicalTrials.gov, 
NCT00493987. 
Interventions 
The study participants endogenous T production was suppressed using a gonadotropin-releasing 
hormone agonist, and artificial levels of circulating T were created by administration of graded 
doses (50, 125, 300, or 600 mg) of T enanthate. The grading was planned to encompass the range 
from sub- to supraphysiological. The graded T doses were administered, additionally either the 
DHT suppressing dutasteride or placebo were given to crated eight groups. The trail lasted 20 
weeks.  
Results of 5a-Reductase Trial important for Study I 
The resulting change in fat-free mass was related to T levels in a dose-dependent manner and there 
was no difference due to DHT suppression. As the suppression of DHT had no effect on fat-free 
mass, the two arms could be combined in Study I, yielding four groups with graded doses of T 
supplementation. 
Study participants 
Study I use data generated in the 5a-Reductase Trial, more specifically T and fT levels and study 
participants with complete MRI scans. 
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Outcome measurements 
The primary outcome was change in cross-sectional axial area of total psoas muscle (PM) at L3.  
The areas of both PM were manually traced, based on methodology by Taguchi et al., where the 
level on which both transverse processes were fully observed is used, and totaled, see Fig 6A.250 
Software used was OsiriX MD version 8.0.2 (Pixmeo, Bernex, Geneva, Switzerland). 
Secondary outcomes were: 
- paraspinal muscles (erector spinae and quadratus lumborum) at L3. (Fig. 6A) 
- total muscle area at L3, including the muscle areas of psoas major; paraspinal; the anterior 
abdominal wall (transverse abdominis, internal and external obliques, and rectus abdominis 
muscles). (Fig. 6A) 
- Obturator internus muscles, using the axial slice containing the largest combined trans-
axial width of the muscle. (Fig. 6D) 
- Ischiocavernosus muscles, using the axial slice containing the largest combined trans-axial 
width. (Fig. 6B) 
- Pelvic floor muscles, i.e. pelvic diaphragm, including the levator ani muscle, using an axial 
slice at the level between the prostate and the penile bulb, excluding the rectum and the 
urethra. (Fig. 6C) 
 
Muscle area measurements were examined both as standardized by division with height-squared 
(primary) and as absolute.  
 
Hormone measurements 
Androgen sampling was done through morning blood samples collected at baseline and at the end 
of the study. Liquid chromatography–tandem mass spectrometry (sensitivity of <0.1 nmol/L) was 
used to measure serum T and DHT.251 The interassay coefficient of variation for T assay was 7.7% 
AW 
PM 
PS 
A C 
B D 
Figure 6. T1-weighted (A-C) and T2 weighted (D) Magnetic Resonance Images of areas measured. A) Muscle areas at 3rd 
lumbar vertebrae, psoas major (PM), paraspinal muscles (PS), abdominal wall (AW). 1B) The ichiocavernosus muscles. 1C) 
The pelvic diaphragm. 1D) The obturator internus muscles. Reprint from study 1. 
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at 8.4 nmol/L, 4.4% at 18.5 nmol/L, and 3.3% at 35.3 nmol/L of T. Free T levels were 
calculated.252 SHBG was measured using an immunofluorometric assay (sensitivity of 2.5 nmol/L). 
Statistical analysis 
Statistical analyses were made using SAS v.9.3 (SAS Institute, Cary, NC, USA) and R software 
v.2.15.1. Descriptive statistics of study participant characteristics and outcomes were presented as 
means and standard deviations. Statistical tests were done two-sided with alpha level 0.05. Model 
assumption and distribution of outcomes were examined graphically. Linear regression models 
were used to assess relationships of muscle areas with T dose and T levels. Linear regression 
models for standardized outcomes were adjusted for baseline measurements, age and SHBG. For 
absolute area measurements, BMI was included in regression models. Parameter estimates of 
outcomes were provided, with 95% CIs, per 100mg/week dose of T enanthate, and partial R-
squared metrics calculated. Relation between serum T and fT levels and muscle outcomes were 
assessed with R-squared and corresponding p-values as well as presented graphically with scatter 
plots. 
Sexual Function and Wellbeing in Males Diagnosed with Rectal Cancer – a 
cohort study 
 
This prospective cohort study was set up after the findings in a the review by Buchli et al., 
concerning adverse impact on fertility and testicular function by RT.191 The hypothesis generated 
by the review was that RT used in multimodal rectal cancer treatment induced acute and late 
adverse effects on testicular function. The adverse effects of RT in focus were infertility and 
hypogonadism, which would have significant impact on functional outcomes and QoL for the 
increasing number of long-term survivors of RC. 
Cohort study design 
Preoperative RT for RC, as determined by the MDT conference was the exposure in this 
longitudinal cohort study. The primary endpoint, serum T, and secondary endpoints included 
spermatogenesis, sexual function and QoL were assessed repeatedly. The study is registered at 
www.clinicaltrials.gov with Clinical Trial ID NCT01216202. The study was to run for two years, 
with yearly follow-ups. The initial sample size was set at 100, assuming a longitudinal decrease in 
mean serum T of 3 nmol/L (SD 6.5 nmol/L) with a two-sided CI of 0.95 and with the aim at 
exceeding a power of 0.80 using 40 pairs of observations and with predicted two thirds being 
exposed and one third lost to follow-up power. 
Criteria 
Inclusion criteria were RC stage I to III, planned for rectal resection, age over 18, fluency in 
Swedish, resident in the Stockholm County and given informed consent. Exclusion criteria were: 
planned for local excision, present or history of urogenital cancer, history of pelvic irradiation, 
androgen related medication or abuse. 
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Changes to protocol 
During the second year of the study it was noted that less than ten percent of the study participants 
were unexposed, i.e. only underwent surgery. Prostate cancer, being an adenocarcinoma in the 
lower pelvis, were deemed similar enough to constitute part of the unexposed group. Thus, patients 
suffering prostate cancer and planed for robot-assisted prostatectomy were included as unexposed, 
given the same criteria.  
Enrollment 
The study started enrollment in April 2010 at the outpatient clinics of the colorectal units at 
Karolinska University Hospital (tertiary referral center) and Ersta Hospital (secondary referral 
center), Stockholm, Sweden. Enrollment ended in May 2014. Study participants with prostate 
cancer were enrolled at the Department of Urology at Karolinska University Hospital between 
May 2012 and January 2013.  
 
In total 372 men with RC were assessed, 188 were found eligible, and 115 men were included. In 
men with prostate cancer, 298 were eligible and 63 were included. The main reason for non-
inclusion was unwillingness to participate.  
Data collection 
Prior to any treatment, study participants visited the Center for Andrology and Sexual Medicine at 
Karolinska University Hospital (Stockholm, Sweden) to submit: clinical reporting form 
information, a fasting morning venous blood sample, questionnaires and a semen sample. The 
same material was collected approximately one and two years after surgery. In addition, 
cryopreservation of semen was offered if aged under 55. Study participants treated with RT had 
an additional pre-operative blood sample collected. Data regarding surgery and related events as 
well as oncological outcomes were retrieved from clinical records. At the one and two years after 
surgery, in addition to the data mentioned above, a test of testicular endocrine capacity was 
performed by injection of human chorionic gonadotropin (hCG), an LH analogue. Study 
participant had the option to meet an andrologist during the study to evaluate possible sexual 
dysfunction or symptoms of LOH. 
 
Study participants could elect to opt out from semen/androgen sampling and/or questionnaires 
at any time without leaving the study. Study participants with prostate cancer were not pertaining 
in semen analysis. 
Ethical approvals 
The study was approved by the Regional Ethical Review Board in Stockholm (2009/1860-31/2), 
as were amendments 2010/1768-32; 2011/2097-32; 2012/2173-32 to allow for a wider inclusion 
and analysis of radiological examinations generated during treatment. 
Exposure 
The exposed group got RT in accordance with MDT recommendations, generating in total 101 
exposed study participants. Short course RT was prescribed in 76, of which 12 had preoperative 
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full-dose chemotherapy (capecitabine and oxaliplatin) under the RAPIDO-trial. Long course 
consisted of mainly 50.4 Gy (n=22), two study participants received 50Gy and one 64.4 Gy. Long 
course RT, except 50 Gy, were administered with concomitant chemotherapy (capecitabine). 
 
Cumulative mean testicular dose was derived from treatment planning CT and, by dividing TD by 
prescribed dose times 100, relative TD was calculated.253 The LH-T ratio was used to assess the 
state of the hypothalamic–pituitary–gonadal axis. Biochemical hypogonadism was defined as 
serum T levels below 8 nmol/L. 
Outcome measurements - Hormones 
Total serum T, LH, FSH and SHBG was analyzed at Karolinska University Laboratory. Total 
serum T and SHBG were measured with chemiluminescence using the Beckman Coulters UniCel 
DxI 800 Instrument (Beckman Coulters, CA, USA), with a coefficient of variance (CV) <10% in 
regards to T levels ranging from 6.94 to 43.70 nmol/L and 5% for SHBG. Bioavailable 
testosterone levels (non-SHBG bound) were derived from measurements of total T, SHBG, and 
albumin. Free T levels were calculated according to Zakharov with a set albumin concentration of 
43g/L. This new method allows for the allosteric characteristics of SHBG as mentioned above. 
Luteinizing hormone was measured with fluorescence immunoassay using PerkinElmers 
AutoDELFIA immunoassay system (PerkinElmers, CT, USA), CV <2%. 
Methods specific to Study II- IV 
Descriptive statistics 
In general, categorical data were reported as frequency (percentage) and continuous data as median 
(range). Groups were compared using Wilcoxon rank-sum or Fisher exact tests (cross-sectional). 
For longitudinal comparisons, Wilcoxon's signed-Rank test or McNamer's test were used. The data 
were analyzed with Stata version 14 (StataCorp LP, College Station, TX, USA). 
Longitudinal regression analysis 
In study II to IV longitudinal regression analysis (LRA) has been the statistical method of choice 
to assess change over time. Longitudinal regression analysis allows for consideration of possible 
confounding or effect modification. In study II and III, LRA based on generalized estimating 
equation (GEE) was used to model population-averaged outcomes accounting for correlation 
between repeated observations and enable evaluation of confounding or effect modification. In 
study IV, LRA based on random-effects models were applied to assess the association between T 
levels and muscle area, and muscle area and metastatic disease. 
Study II 
The effect of RT on long-term endocrine testicular function was assessed. The cohort included 91 
men in the exposed group and 72 in the unexposed (59 with prostate cancer).  
Outcome 
Hormonal change was related to group, exposed or non-exposed, and to cumulative mean TD. 
Oncological outcome in RC study participants, time-to-recurrence, was collected from clinical 
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data. Detection of local recurrence, systemic disease and rectal cancer-related death were registered 
as events, non-cancer related death was censored. Oncological outcome was related to levels of 
LH at one-year follow-up to elucidate possible association between elevated LH levels one year 
postoperatively and development of cancer recurrence after uneventful one-year-follow-up. 
Elevated LH was defined as individual increase in LH of more than 50% between baseline and 
one-year follow-up. 
Statistical analysis 
Longitudinal regression analysis using GEE models. In group comparison, the reported 
coefficients represent the mean change differences between exposed or non-exposed. In TD 
analysis the coefficients describe the average change in androgen levels per one Gy increase of TD. 
Final models were adjusted for age, BMI and The American Society of Anesthesiologists (ASA) 
physical status classification. In the oncological analysis, the Kaplan-Meier method was used and 
groups were compared by log rank tests. 
Study III 
In Study III, a longitudinal observational sub-study using material from the cohort in Study II, 
severe postoperative adverse events were related to TD and preoperative change in T due to RT 
in 104 men with RC.  
Outcome 
Postoperative adverse events (AE) within 30 days after surgery, were recorded and graded 
according to Clavien-Dindo.105 Grade of three or more was considered as severe, grade 3 defined 
as AEs that resulted in surgical, endoscopic or radiological intervention, grade 4 as AEs requiring 
IC/ICU management and grade 5 as death. The highest graded postoperative AE for each study 
participant was used. 
Statistical analysis 
Generalized estimating equation, with binomial distribution and robust variance estimator, were 
used. All models were adjusted for elapsed time between RT and surgery, to account for the initial 
decline in serum T and the subsequently responding increase in LH.95 Final models were adjusted 
for age, BMI and ASA-score to reflect their impact on the hypothalamic-pituitary-gonadal axis.254 
Factors that did not change the point estimates more than 10% (smoking, tumor stage, distance 
from the anal verge and type of surgery) were omitted in the final models. 255 
Study IV 
This study was also based on the cohort study described above. It included 102 study participants 
with RC and adequate CT/MRI examinations at baseline. Exposure was change in T, related to 
RT, and outcomes were change in select skeletal muscles. Further, change in skeletal muscle was 
related to systemic cancer recurrence. 
Outcomes 
The primary endpoint was the combined area of left- and right-sided psoas major (PM) at L3. 
Secondary endpoints were total muscle area, sarcopenia (defined as total PM area <5 cm2/m2), PM 
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height and width as well as average attenuation for each separate muscle area. All muscle 
measurements were manually traced on axial slices at the level of the 3rd lumbar vertebra of MRI 
or CT scans using OsiriX MD version 8.0.2 (Pixmeo, Bernex, Geneva, Switzerland). Oncological 
outcome, defined as cancer recurrence in the form of systemic disease, within five years of surgery, 
was collected from study participants journals.  
Statistical analysis 
Longitudinal regression models with random-effects were used. The models were adjusted for 
elapsed time between baseline and one-year follow-up imaging, and body weight. Body weight as 
it was found to have a stronger relation to muscle area than the usually considered height. 
Models in oncological analyses were adjusted for fT, its association with muscle area verified in 
this study and previously shown. Possible confounders did not change point estimates more than 
10%. 
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Results 
Study I 
Telephone screening covered 3,792 men of which 189 were eligible and 139 randomized. One-
hundred-two study participants completed the study. In total 76 study participants had adequate 
MRI scans at baseline and at the end of study. Mean age was 37.6 (SD 8.7) and mean BMI 26.3 
(SD 4.0).  
Hormones 
Concentrations of T and fT had a positive linear association with administrated T dose, (p<0.001, 
partial R2=0.215 and p<0.001, partial R2=0.203 respectively). 
Longitudinal anabolic effect in skeletal muscle 
The average standardized PM area decreased with 4.8% in the 50 mg/week T enanthate dose 
regimen, and increased with 9.7% in the 600 mg/week T enanthate dose regimen. There was a 
dose-dependent increase in muscle area, e.g. standardized PM estimated increase per 100mg T 
enanthate was 0.622 cm2 (95% CI 0.394-0.850) (Table 4). The association between both absolute 
and standardized PM were repeated in the paraspinal muscles and in the abdominal wall and total 
abdominal muscles, see Figure 7 and Table 4. 
 
 
Figure 7 Testosterone dose effect on the cross-sectional area of abdominal and pelvic muscle groups. Bar charts indicate the 
change in standardized muscle area from baseline in each dose group. Results represent sample means and 95% confidence 
intervals. p-values for dose effect extracted from multiple linear regression model adjusted to baseline value, age, and SHBG. 
Reprint from Study I. 
 
 
The findings of muscle area sensitivity visive T dose were similar for fT, see Figure 8.  
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Figure 3. Dose−response of Standardized Muscles (muscle area measurements are reported in 
 squared−centimeter and were standardized by dividing it by height in squared−meter)
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In the pelvic muscles, the obturator internus and ischiocavernosus muscle, had comparable 
associations, even if the latter did not reach the same level of significance (Table 4). The increase 
in average area of the ichiocavernosus muscle in the highest T dose regimen was 22%. In the 
composite area of the pelvic floor muscles, there was an association between muscle area change 
and T dose (p<0.001, partial R2 = 0.402). 
 
Table 4 Estimated values of muscle area change per dose increase. 
 
Muscle area change is expressed in square centimetres. Standardized (Std)=cm2/m2. * = Values presented for parameter 
estimates and 95% CIs of muscle area change are per 100 mg increase of weekly dose testosterone enanthate. **Overall R-
squared values for linear regression model with adjustments. Reprint from Study I. 
 
significant dose–response relationship was seen between the
testosterone dose and the change in pelvic floor muscles, includ-
ing levator ani (p < 0.001, partial R2 = 0.402).
DISCUSSION
The present study shows that exogenous testosterone
administration induced a dose-dependent increase in the mus-
cles of the trunk and pelvis. Additionally, testosterone admin-
istration dose-dependently increased the hip-stabilizing
obturator internus muscle and also the ischiocavernosus mus-
cle that has an important role in erectile function. These
results are consistent with a previous small study showing that
testosterone replacement increased volume of the paraspinal
muscles in hypogonadal men (Leifke et al., 1998). We also
show that increments in the area of these trunk and pelvic
muscles were correlated with on-treatment total and free
serum testosterone levels. These findings suggest that these
muscle groups in men are as responsive to testosterone
administration as the appendicular muscles and can be poten-
tial targets of intervention in frail older men who are at risk
for falls and men who have pelvic floor disorders (Granacher
et al., 2008, 2013).
Table 3 : Estimated values of muscle area
change per dose increase Muscles Estimate (95% CIs) p-value* R-squared
of the Model**
Partial R2 of
dose effect
Psoas Major, PM 0.622 (0.394, 0.850) <0.001 0.307 0.297
Std PM 0.204 (0.133, 0.274) <0.001 0.332 0.311
Paraspinal muscles, PS 1.789 (1.317, 2.261) <0.001 0.466 0.450
Std PS 0.569 (0.426, 0.711) <0.001 0.483 0.468
Abdominal wall, ABDW 2.530 (1.627, 3.434) <0.001 0.408 0.340
Std ABDW 0.797 (0.527, 1.066) <0.001 0.405 0.527
Skeletal muscle index 5.434 (3.989, 6.879) <0.001 0.535 0.481
Std SMI 1.640 (1.210, 2.071) <0.001 0.525 0.494
Ischiocavernosus, IC 0.082 (0.003, 0.045) 0.041 0.157 0.068
Std IC 0.025 (!0.001, 0.050) 0.060 0.117 0.059
Obturator internus, OB 0.455 (0.233, 0.678) <0.001 0.279 0.175
Std OB 0.151 (0.082, 0.219) <0.001 0.294 0.192
Muscle area change is expressed in square centimeters. Standardized (Std) muscle change was defined as mus-
cle change divided by height-squared (cm2/m2). *Values presented for parameter estimates and 95% CIs of
muscle area change are per 100 unit increase (increase of 100 mg of testosterone enanthate per week) in the
dose regimen. **Overall R-squared values for linear regression model with adjustments.
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Figure 3 Testosterone dose effect on the cross-sectional area of abdominal and pelvic muscle groups. Bar charts indicate the change in standardized muscle
area from baseline in each dose group. Results represent sample means and 95% confidence intervals. p-Values for dose effect extracted from multiple linear
regression model adjusted to baseline value, age, and SHBG. [Colour figure can be viewed at wileyonlinelibrary.com].
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Figure 8. Scatter plots of change in standardized muscle area on total and free testosterone level change. R2 and p-values 
represent association between standardized muscle area and total and free testosterone level change calculated from linear 
regression model. Reprint from Study I. 
 
 
 
 
  
The core muscles of the trunk are considered ‘dynamic stabi-
lizers’, and they play a vital role in providing stability and func-
tional movement to the vertebral column; atrophy of these
muscles can lead to spinal instability and predisposition to falls
(Danneels et al., 2000; Kim et al., 2014). Similar to appendicular
muscles, the core muscles also undergo atrophy in wasting con-
ditions. For example, among patients with hypercortisolemia
and liver cirrhosis, significant atrophy of the psoas major muscle
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Figure 4 Scatter plots of standardized muscle area change on total and free testosterone level change. R 2 and p -values represent association between
standardized body composition and total and free testosterone level change calculated from simple linear regression model. [Colour figure can be viewed
at wileyonlinelibrary.com].
70 Andrology, 2018, 6, 64–73 © 2017 American Society of Andrology and European Academy of Andrology
J. Tapper et al. ANDROLOGY
42│RESULTS  
 
Study II 
In total 91 irradiated and 72 unexposed men were analysed at baseline, see Figure 9. 
 
 
Figure 9. Study participant flow chart. 
Median age was comparable in irradiated 63 (32-82) years vs. 63 (50-86) years in unexposed 
(p=0.336). The irradiated study participants had a lower BMI (25.2 kg/m2 vs 26.5 kg/m2, p=0.017). 
In the irradiated, there was a trend towards a higher ASA-score (p=0.062). Median T levels were 
Long-term effects on the testis by RT in rectal cancer treatment. 16 
Figure 1. Study participant flow chart.  
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Assessed for eligibility, rectal cancer 
patients, n = 372 
Eligible, n = 188 
• Stage IV disease n=62 
• Referred after radiotherapy n=44 
• Urogenital malignancy n = 43 
• Language/communication restrictions n = 32 
• No rectal resection n = 2 
• Testosterone replacement = 1  
• Declined to participate n = 46 
• Missed to include n = 19 
• Declined surgery n = 2 
• Other n = 6 
 Included, n =115 
n = 51 
Prostate cancer patients, included, n = 63 
Eligible prostate cancer patients, n = 245 
Preoperative radiotherapy (RT),  
n = 91 
n = 13 
• Declined to participate further n=5 
• Missed baseline visit n = 4 
• Died n = 2 
 
n = 60 
• Anti-androgen treatment n=2 
• Re-operated n = 1 
• Radiated n = 1 
 
• Declined to participate n = 75 
• Missed to include n = 107 
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the same, 11 nmol/L (irradiated range 4-22 nmol/L vs unexposed 5.4-25 nmol/L, p=0.444), at 
baseline. Other hormonal levels did not differ either. 
 
Out of the 163 men included, 95 had complete two-year follow-up. Hormone levels were 
comparable in men with complete follow-up versus men lost to follow-up of the non-irradiated 
group. In irradiated men, there was a larger proportion of biochemical hypogonadism in those 
lost to follow-up, 26.8 % vs. 5.77 %, p=0.004. They also had higher LH levels (4.25 vs. 3.6 IU/L, 
p=0.047) and, correspondingly, larger LH-T ratio (0.43 vs. 0.29, p=0.020) at baseline compared 
to men with complete follow-up.  
Hormonal Change 
One year after surgery, irradiated men had increased median levels of LH and FSH (5.1 vs 3.45, 
p<0.001 and 12 vs 5.45, p<0.001, respectively). The ratio of LH/T was higher in the irradiated 
compared to the unexposed as well, 0.52 vs 0.33 (p<0.001). After two years, there were no cross-
sectional differences between groups. The levels of LH, FSH and the LH/T-ratio were significantly 
increased compared to baseline in irradiated men, see Table 5. 
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Table 5. Hormone profiles. 
 
  
RT- RT+ p value, Wilcoxon rank-sum test
Baseline
Serum T (nmol/L) 11 (5.4 - 25) 11 (4 - 22) 0.444
Free T (pmol/L) 332 (131 - 680) 319 (89.7 - 551) 0.390
LH (IU/L) 3.7 (1 - 16) 4.1 (1.6 - 13) 0.458
FSH (IU/L) 5.6 (1.6 - 33) 4.7 (1.2 - 19) 0.066
LH/T-ratio (IU/nmol) 0.33 (0.09 - 2.5) 0.35 (0.11 - 2.10) 0.165
Post RT follow up
Serum T (nmol/L) 8.9 (0.8 - 18)**
Free T (pmol/L) 0.243 (16.8 - 534)**
LH (IU/L) 4.9 (1.6 - 16)**
FSH (IU/L) 8.5 (2 - 30)**
LH/T-ratio (IU/nmol) 0.56 (0.15 -5.93)**
1-year follow up
Serum T (nmol/L) 11.5 (5.5 - 22) 11 (5.5 - 18) 0.394
Free T (pmol/L) 334 (146 - 601) 302 (160 - 502) 0.077
LH (IU/L) 3.45 (1.6 - 9.7) 5.1 (1.7 - 13)** <0.001
FSH (IU/L) 5.45 (1.4 - 27) 12 (0.07 - 40)** <0.001
LH/T-ratio (IU/nmol) 0.33 (0.12 - 0.99) 0.52 (0.11 - 1.48)** <0.001
dT, hCG-test (nmol/L) 11.05 (-6.1 - 30) 12.05 (-4 - 25.3) 0.941
2-year follow up
Serum T (nmol/L) 10 (4.6 - 21)** 11 (4.2 - 16) 0.499
Free T (pmol/L) 272 (130 - 545)** 322 (132 - 493) 0.549
LH (IU/L) 3.75 (1.6 - 9.9) 4.1 (0.9 - 16)** 0.367
FSH (IU/L) 5.75 (2.6 - 27) 6.15 (0.09 - 41)** 0.727
LH/T-ratio (IU/nmol) 0.36 (0.14 - 1.09)* 0.39 (0.08 - 1.33)** 0.313
dT, hCG-test (nmol/L) 11 (1.7 - 23)* 14 (1 - 38) 0.105
Notes RT = Radiotherapy. Testosterone (T), Luteinizing hormone (LH), LH/T-ratio, 
Follicle stimulating hormone (FSH) and hCG (human chorionic 
gonadotropin, Pregnyl) response tests are reported as median, range. */** 
=Significant change from baseline p<0.05/0.005 respectively.
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Longitudinal regression analysis 
Longitudinal regression analysis confirmed a preoperative drop in T and fT levels, and increase in 
LH, FSH and LH/T-ratio. Figure 10 graphically displays predicted means with 95% CI. 
 
Figure 10. Predicted means of hormones. Range illustrates 95% confidence intervals.   
 
The effect of TD on hormone levels are described in Table 6. Cumulative mean testicular dose 
was dose-dependently related to decrease in T preoperatively, decreasing mean T with 0.40 nmol/L 
per Gy (CI 95%: -0.66 - -0.14, p=0.002). Preoperative fT was similarly impacted. Luteinizing 
hormone, FSH and LH/T-ratio showed dose-dependent increases, both pre- and postoperatively. 
  
9
10
11
12
13
1 2 3 4
Testosterone (T), nmol/L
25
0
30
0
35
0
1 2 3 4
Free T, pmol/L
3
4
5
6
7
1 2 3 4
Luteinizing Hormone (LH) IU/L
5
10
15
20
1 2 3 4
Follicle Stimulating Hormone IU/L
.3
.4
.5
.6
.7
.8
1 2 3 4
LH/T−ratio
Unexposed Irradiated
46│RESULTS  
 
 
 
Table 6. Longitudinal regression analysis of hormone changes over study period in relation to mean 
 cumulative testicular dose. 
 
Mean change for 
each Gy of TD 
95% Confidence 
interval p 
Testosterone (nmol/L) 
   
Preoperative -0.40 -0.66 - -0.14 0.002 
Postoperative -0.01 -0.43 - 0.40 0.946 
Free Testosterone 
(nmol/L) 
   
Preoperative -15.2 -23.3- -7.06 <0.001 
Postoperative -0.51 -13.5 - 12.5 0.939 
LH (IU/L) 
   
Preoperative 0.36 0.16 - 0.56 <0.001 
Postoperative 0.62 0.31 - .0.93 <0.001 
FSH (E/L) 
   
Preoperative 1.14 0.65 - 1.63 <0.001 
Postoperative 2.94 2.17 - 3.71 <0.001 
LH/T-ratio 
   
Preoperative 0.07 0.03 - 0.11 0.001 
Postoperative 0.06 -0.00 - 0.12 0.057 
Notes: TD = cumulative mean testicular dose.  LH = Luteinizing Hormone. FSH = 
Follicle Stimulating Hormone. T = Testosterone. Models adjusted for age, BMI and The 
American Society of Anesthesiologists (ASA) physical status classification. 
 
Oncological outcome 
After one year, LH levels of 64 study participants treated for RC without clinical and radiological 
evidence of cancer recurrence were available. Twenty-one of them had an LH increase by more 
than 50% (LH-elevated), the remaining 43 men had a less prominent change in LH (LH-stable). 
The groups, LH elevated and LH-stable, were comparable regarding age, ASA-score, cTNM, 
proportion of RT, type of surgery and perioperative markers for extensive surgery.  
 
In the LH-elevated group there was eight failures (distal metastasis n=7 and LR n=1), with a rate 
of 9.90 per 100 person-year. In the LH-stable group there was six failures (distal metastasis) and a 
rate of 3.10 per 100 person-year. The incidence rate ratio of RC recurrence in LH-elevated was 
3.19 (95% C.I.: 0.97-11.2, mid-p=0.036) compared to LH-stable. Kaplan-Meier plot is displayed 
in Figure 11 (log-rank test: p=0.032).  
 RESULTS│47 
 
 
Figure 11. Cumulative incidence of rectal cancer recurrence, months after surgery. 
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Study III 
Out of 104 study participants, 26 had severe postoperative AE (AE+), equaling a cumulative 
incidence of 25%. Baseline characteristics, including clinical tumor stage and treatment, did not 
differ, but AE+ had longer median hospital stay 16 (range: 4-46) days vs. AE- with 9 (4-31) days 
(p < 0.001) (Table 7).  
Table 7. Baseline characteristics and treatment specific factors. Reprint from Study III. 
 
Clavien 0-2 Clavien 3+ p
Number of participants 78 26
Age (Years) 63.5 (36-82) 63 (32-86) 0.816†
BMI (kg/m2) 24.8 (16.1-35.3) 26.2 (20.8-40.6) 0.145†
ASA-score
 I 17 (22) 4 (15.5)
 II 41 ( 52.5) 18 (69) 0.372*
 III 20 (25.5) 4 (15.5)
No. of comorbitidies
 0 30 (38.5) 10 (38.5)
 1 18 (23) 9 (34.5) 0.446*
 ≥2 30 (38.5) 7 (27)
Current smoker
 No 68 (87) 22 (85)
 Yes 10 (13) 4 (15)
Radiological tumor stage
 T2 9 (11) 6 (23)
 T3 a/b 35 (45) 11 (42)
 T3 c/d 10 (13) 3 (12)
 T4 24 (31) 6 (23)
Radiological lymph node status
 N0 29 (37) 13 (50)
 N+ 49 (63) 13 (50)
Tumor distance from anal verge (cm) 8 (1-15) 7 (1-14) 0.595†
Neoadjuvant treatment
 None 10 (12.8) 3 (11.5)
 25 Gy, direct surgery 30 (38.5) 11 (42.3)
 25 Gy, delayed surgery 8 (10.2) 7 (26.9)
 25 Gy, chemotherapy and delayed surgery 10 (12.8) 1 (3.9)
 50 Gy 2 (2.6) 0 (0)
 50.4 Gy and concomittant chemotherapy 18 (23.1) 4 (15.4)
Cumulative mean testicular dose, TD (Gy) 0.660 (0-14.369) 0.461 (0-14.193) 0.571†
Realtive TD (TD/Total dose*100) 2.301 (0-57.477) 1.513 (0-56.773) 0.571†
Time between radiotherapy and surgery (days) 34 (1 - 192) 41 (3 - 188) 0.755†
Type of resection
 Anterior resection 54 (69) 15 (58)
 Abdominoperineal excision 24 (31) 11 (42)
Surgical operation time (minutes) 304 (163-605) 332 (141-857) 0.504*
Blood loss during surgery (mL) 600 (25-2800) 500 (150-16600) 0.783*
Length of hospital stay (days) 9 (4-31) 16 (4-46) 0.000†
0.746*
Notes: Continous variable reported as median (range), Categorical data reported as frequency (percentage), *=Fisher´s 
exact test, †=Wilcoxon rank-sum test, ASA = American Society of Anesthesiologists, Gy = Gray.
0.573*
0.340*
0.539*
0.258*
 RESULTS│49 
 
Hormones and laboratory measurements  
Preoperative levels of T fT and LH were similar in men with and men without severe postoperative 
AE. The median LH/T-ratio was higher in AE+ with 0.603 (0.2-2.5) vs 0.452 (0.13-5.93) for AE- 
(p = 0.035). In the AE+ group, median T decreased with 24% from baseline to preoperative 
samples, in AE- the same comparison yielded 13%. Preoperative laboratory markers, such as C-
reactive protein and white cell blood count, did not differ between groups, see Table 8. 
 
Table 8. Hormones and laboratory markers. Reprint from Study III. 
 
  
Clavien 0-2 Clavien 3+
Baseline hormones p
Testoterone (nmol/L) 11 (4.2-22) 11.5 (4-17) 0.949†
Free testosterone (pmol/L) 318.0 (89.7 - 665.7) 311.7 (100.5-496.3) 0.828†
Luteinizing Hormone (IU/L) 4 (1.6-13) 4.7 (2-16) 0.127†
LH/T-ratio 0.342 (0.11-2.097) 0.460 (0.182-2.5) 0.118†
Proportion with Testosterone < 8 nmol/L 11 (14) 5 (19) 0.539*
Preoperative hormones 
Testoterone (nmol/L) 9.6 (0.8-22) 8.7 (2.4 - 17) 0.286†
Free testosterone (nmol/L) 0.266 (0.017-0.666) 0.254 (0.046-0.534) 0.276†
Luteinizing Hormone (IU/L) 4.6 (1.6-16) 5.3 (2.1-16) 0.107†
LH/T-ratio 0.452 (0.127-5.926) 0.603 (0.2-2.5) 0.035†
Proportion with Testosterone < 8 nmol/L 22 (28) 10 (38) 0.337*
Labratory markers
Preoperative
C-reactive protein 3 (1-38) 4 (1-50) 0.243†
White cell blood count 5.45 (3.1-11.8) 5.6 (3.7 - 11) 0.190†
Albumin 38 (28-45) 38 (30 - 43) 0.905†
Postoperative, day 1 after surgery
C-reactive protein, mg/L 85 (22-196) 100 (45-219) 0.341†
White cell blood count, Units x 109/L 7.8 (3.7 - 11.4) 8.5 (4.5 - 23.8) 0.432†
Albumin, g/L 26.5 (22-35) 26.5 (22-30) 0.918†
Notes: Continous variable reported as median (range), Categorical data reported as frequency 
(precentage) † = Wilcoxon rank-sum test, * = Fischer´s exact test.
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Longitudinal regression analysis 
The longitudinal regression analysis found that change in T had a suggested inverse relationship 
with severe postoperative AE (OR: 0.878, 95% CI 0.759-1.015, p = 0.078). Adjusting for age, BMI 
and ASA-score strengthened this to a significant inverse association between preoperative change 
in T and severe postoperative AE, OR 0.844 (95% CI 0.720-0.990, p = 0.034), illustrated in Figure 
12. This translates to a OR of 1.18 to suffer a severe postoperative AE for one unit decrease of T 
between baseline and preoperative sampling. Increase in LH/T-ratio induced a OR 2.020 (95% CI 
1.010-4.039, p = 0.047) for severe postoperative AE. 
 
 
Figure 12. Predicted risk of severe postoperative adverse events graded 3+ according to Clavien-Dindo in relation to the 
preoperative change in serum testosterone. The curve describes the expected change in risk for severe postoperative adverse 
event with 95% confidence interval related to the preoperative change in serum testosterone. Reprint from Study III. 
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Study IV 
Complete CT scans and hormone analyses of 102 men were available with RC stage I to III at 
baseline. Median age was 63.5 (32-86) years, median BMI 25.5 (16.1-40.6) kg/m2 and 77.5% had 
ASA score I-II. At one-year follow-up, 66 study participants had submitted hormone samples. 
Comparing to baseline, median LH level and LH/T-ratio had increased. 
Longitudinal muscle change 
Psoas major could be traced for 92 study participants (CT n=78 and MRI n=14), and SMI could 
be analyzed in 86. Some examinations were done at the pelvic and upper abdominal/lung areas 
separately, omitting the L3 level. 
 
Psoas major area did not change statistically, 18.6 (7.5-32.0) cm2 at baseline compared to 19.4 (9.4-
34.0) cm2 at follow-up (p=0.743) but attenuation increased from 41.4 (16.5-60.0) HU to 47.6 (27.2-
71.3) HU (p<0.001). The proportion of sarcopenic PM decreased from 19.6% to 12.0% (p<0.001). 
Median total skeletal muscle area and SMI decreased (-11 cm2, p=0.042 and -2.7 cm2, p=0.029 
respectively), while attenuation of total muscle area increased (p<0.001).  
 
Longitudinal regression analysis found significant associations between changes in PM area and 
changes in fT, LH and LH/T-ratio in men with complete hormone samples at one-year follow up 
(Table 9). There was also a relationship between PM attenuation and fT. Changes in total muscle 
area was associated to changes in all hormones. Excluding right psoas width, fT was associated 
with all muscle measurements. Change in all muscle areas were associated with the LH/T-ratio. 
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Table 9. Longitudinal analysis of muscle changes in relation to hormones. 
 
 
Oncological outcome 
Out of the 102 participants, 28 had distant metastases and one had a LR registered as first cancer 
related event postoperatively. Two study participants had systemic disease discovered already 
during the perioperative period and were excluded from this analysis. Of the 28 study participants 
suffering distant metastasis, 22 had complete CT/MRI examinations at baseline and at, and six of 
those 22 had distant metastasis discovered prior to the one-year follow-up. Psoas major attenuation 
and right psoas height were related to metastases in all 22 with complete CT/MRI examinations, 
see Table 10. A negative change in total muscle area and SMI were associated with distant cancer 
recurrence. Sub-analysis of later metastases, in those 16 study participants diagnosed after to the 
follow-up, found a more distinct association between total muscle area measured at one-year and 
later metastases (-7.88 (-13.6 - -2.21) cm2, p=0.006).   
 
 Longitudinal change per unit in image analysis 
 Serum Testosterone P Free testosterone P Luteinizing Hormone P  LH/T-ratio P 
Psoas major         
 area 11.7 (-3.51 - 26.8) 0.132 0.70 (0.21 - 1.18) 0.005 -20.6 (-38.5 - -2.71) 0.024 -223 (-376 - -70.5) 0.004 
 attenuation 0.27 (-0.16 - 0.69) 0.218 0.02 (0.00 - 0.03) 0.011 -0.36 (-0.83 - 0.11) 0.137 -3.58 (-7.42 - 0.27) 0.068 
         
Total muscle         
 area 0.79 (0.11 - 1.47) 0.022 0.04 (0.02 - 0.06) <0.001 -0.85 (-1.58 - -0.12) 0.022 -8.43 (-14.7 - -2.11) 0.009 
 attenuation 0.47 (0.00 - 0.94) 0.049 0.03 (0.01 - 0.04) 0.001 -0.32 (-0.85 - 0.21) 0.239 -3.33 (-7.77 - 1.12) 0.142 
         
Left psoas major        
 area 6.83 (-0.97 - 14.6) 0.086 0.36 (0.11 - 0.61) 0.004 -8.22 (-17.5 - 1.03) 0.082 -99.6 (-178 - -20.4) 0.014 
 height 0.24 (0.01 - 0.48) 0.042 0.01 (0.00 - 0.02) 0.021 -0.23 (-0.52 - 0.06) 0.114 -2.45 (-4.83 - -0.07) 0.043 
 width 0.19 (-0.06 - 0.43) 0.132 0.01 (0.01 - 0.02) 0.001 -0.15 (-0.45 - 0.15) 0.335 -1.78 (-4.22 - 0.66) 0.153 
 attenuation 0.23 (-0.23 - 0.69) 0.327 0.02 (0.00 - 0.03) 0.038 -0.33 (-0.83 - 0.18) 0.210 -3.33 (-7.50 - 0.83) 0.116 
         
Right psoas major        
 area 5.25 (-2.96 - 13.5) 0.210 0.35 (0.08 - 0.61) 0.009 -12.3 (-22.0 - -2.64) 0.013 -123 (-206 - -41.4) 0.003 
 height 0.20 (-0.04 - 0.43) 0.100 0.01 (0.00 - 0.02) 0.016 -0.24 (-0.52 - 0.03) 0.084 -2.72 (-5.02 - -0.42) 0.021 
 width 0.03 (-0.22 - 0.28) 0.822 0.01 (-0.00 - 0.01) 0.095 -0.27 (-0.57 - 0.04) 0.084 -2.01 (-4.50 - 0.47) 0.113 
 attenuation 0.41 (0.01 - 0.80) 0.044 0.02 (0.00 - 0.03) 0.001 -0.42 (-0.89 - 0.05) 0.077 -4.37 (-8.15 - -0.60) 0.023 
         
Notes: Total muscle area is measured in cm2, psoas major area is measured in mm2, height and 
width are measured in cm, attenuation in Hounsfield units. Adjusted for weight (kg) and time 
(days) elapsed between hormone samples. 
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Table 10 Longitudinal analysis of muscle change and recurring systemic rectal cancer. 
 
  
  
Longitudinal change in image analysis 
due to metastases P  
   
Psoas major area -53.3 (-164.5 - 58.0) 0.348 
 attenuation 5.34 (0.91 - 9.78) 0.018 
   
Total muscle area -5.96 (-10.7 - -1.24) 0.013 
 attenuation 4.14 (-0.32 - 8.60) 0.069 
   
Skeletal Muscle 
Index -1.96 (-3.48 - -0.43) 0.012 
   
Left psoas major   
 area -16.2 (-73.1 - 40.7) 0.577 
 height -1.38 (-3.18 - 0.42) 0.132 
 width 1.59 (-0.50 - 3.68) 0.136 
 attenuation 5.55 (0.91 - 10.2) 0.019 
   
Right psoas major   
 area -36.6 (-97.7 - 24.5) 0.240 
 height -1.89 (-3.65 - -0.12) 0.036 
 width 0.55 (-1.57 - 2.67'9 0.611 
 attenuation 5.16 (0.78 - 9.54) 0.021 
   
Notes: Total muscle areas are measured in cm2, psoas major areas are measured 
in mm2, height and width in mm, attenuation in Hounsfield units, height/width in 
cm. Adjusted for weight (kg) and free Testosterone 
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Discussion 
Androgen sensitivity of appendicular muscles has been shown before, which was not the case for 
human abdominal and pelvic muscles. Study I demonstrated a dose-dependent relationship 
between T and specific skeletal core muscles. This allows for wider considerations of the impact 
of hypogonadism, e.g. loss of balance and falls with subsequent morbidity, as well as possible 
treatment for pelvic floor weakness.  
The long-term effects of RT, using modern RT techniques, were explored in Study II. On average, 
T and fT levels recuperated within two years after surgery. The median levels of LH and FSH as 
well as the LH/T-ratio were increased after two years in irradiated men, compared to baseline, 
indicating an increased degree of compensated hypogonadism. Longitudinal changes in hormones 
were associated with TD, previously not shown in RC. Elevated LH levels after one year tripled 
the risk of systemic cancer recurrence, a possible reaction to systemic disease before metastases 
are discernible with current follow-up regimen.  
In the short term, Study III presented the novel finding that preoperative testicular failure due to 
RT is related to severe postoperative AE. Anabolic effects of T may play an important role in 
limiting the systemic inflammatory response on surgical trauma. 
Study IV validated earlier findings that PM and abdominal muscles are associated with androgen 
levels in study participants treated for RC with RT. Loss of total muscle area at the 3rd lumbar 
vertebra and changes in PM composition were associated with later systemic cancer recurrence, 
another possible indication of systemic disease before discernible metastases. 
Interpretation 
The finding that abdominal and pelvic muscles are at least as responsive to androgens as the 
appendicular muscles were somewhat anticipated due to the known anabolic effects of T. A small 
study had also shown similar results in hypogonadal men in regards to paraspinal muscles.226 
Atrophy of the core muscles, e.g. in wasting conditions such as liver cirrhosis or prolonged bed 
rest, may lead to instability and predisposition to falls.256-260 Common chronic low back pain, 
associated with atrophy of the abdominal muscles, predisposes to mobility limitation and loss of 
balance.261 This new evident data allows for educated further studies of these muscles in differing 
conditions, including sarcopenia and frailty, where treatment might be beneficial for short- and 
long-term outcomes. Especially, core stabilizing abdominal muscles and the pelvic muscles could 
possible targets for treatment in older men suffering from frailty or pelvic floor disorders.222, 223 In 
regards to surgical settings, for total knee arthroplasty there seems to be faster recovery in study 
participants treated with anabolic steroids, but so far studies have been small and no general 
recommendation exists.262 As shown in Study I, MRI allows for solid and reproducible research in 
this field. 
 
The general knowledge regarding RT in RC treatment was that outdated RT induced Leydig cell 
damage to varying, individual, degree and within differing timespans. In the present cohort study, 
a larger and/or more structured group was studied than previously done. The results of average 
recuperation of T and fT levels tells us that, with current RT methodology, the average T levels 
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recovers within two years. The novel finding that TD does have an association with long-term 
hormonal change verifies the casual relation between RT and adversely affected hormone levels. 
The signs of increased compensated hypogonadism do also suggest that, even if average 
recuperation of T levels is present after two years, Leydig cells may not be not fully restored. 
Permanent Leydig cell dysfunction may result in increased long-term risk of morbidity and 
mortality linked to strained or overtaxed androgen production. Increased levels of LH have been 
associated with several morbidities as well mortality, causation still remains uncertain however, but 
not to RC cancer recurrence prior to this study. The process linking elevated LH and RC 
recurrence cannot be elucidated in this material but LH seems to be a possible marker for later 
systemic disease and could compliment decision making regarding treatment and follow-of 
regimens.  
A preoperative decrease in T levels after RT resulted in increased risk of suffering severe 
postoperative AE. This finding perhaps mirrors part of the results in the Stockholm III study, 
showing that the group with sRT and delay suffered fewer complications than those that were 
operated without delay. The delay may have allowed for Leydig cell recuperation, if possible. It 
could also be part of an explanation to why men suffer more postoperative adverse events than 
women. In the literature, endocrine testicular function in regards to RC treatment outcomes is 
limited. In a study encompassing abdominal surgery, low T was a risk factor for postoperative 
complications and T levels decreased by surgery have been shown to recover slower after 
postoperative AE.263 It is possible that RT-induced T level decrease, T being the main anabolic 
hormone in men, adversely impacts postoperative healing by shifting the body towards a more 
catabolic hormonal state and also by modulating systemic inflammatory response on surgical 
trauma. 
Body composition changes in RC patients were linked to changes in androgen levels, in line with 
the findings in Study I regarding generally younger, healthy men. This finding adds further to the 
knowledge regarding androgen effect on muscles in men. Due to damages to nerves and 
microvasculature in multimodal RC treatment, the symptoms used in diagnosis of hypogonadism 
may be unreliable. In this, longitudinal muscle loss measured on routine CT/MRI examinations 
might be a supplementary marker of hypogonadism. Muscle loss may also herald occult cancer 
disease, it has been shown in pancreatic cancer up to five years prior to diagnosis. 264, 265 In CRC 
patients, metastatic seeding can occur in some patients before the carcinoma is detectable using 
routine examinations.266 This means that sarcopenic signs present at baseline or follow-up may 
point at occult metastases, and that under those circumstances, a more advanced treatment 
regimen than recommended today may be beneficial. 
Limitations and validity 
The MRI examinations in Study I were not optimized for the analysis performed, hence not all 
examinations covering all areas of interest, but using manual tracing allowed for exact tracking of 
muscle boundaries and compensation for potential image artifacts making the most of the existing 
images. Given that the trial was not designed for evaluation of trunk and pelvic muscles, the result 
of this study should be viewed as exploratory. By using a single experiences investigator, inter-
observer variability was nullified. Interobserver variance was tested well within standard. The study 
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was relatively small but still the largest to date in this setting. The randomized double-blind study 
design is a strength as well as the comprehensive range of T dosage used. 
The Cohort 
The androgen levels at baseline were not associated with group assignment, which was in effect 
decided independently at the MDT conference, type of cancer or type of preoperative oncological 
treatment. This reduces the risk of selection bias. The study was not large enough to distinguish 
eventual differences between RT regimens. Misclassification of exposure was not an issue, and 
exposure was quantified by calculation of cumulative mean TD from planning CT scans.  
 
Treatment with APE was 37% in the exposed group, a larger proportion than in the general 
population of men presenting with RC. As PTV thereby will include the pelvic floor, leading to 
higher TD, the effect of RT on endocrine testicular function may not be representative for the 
general population. Type of surgery was not associated with the amount of testicular failure. The 
exposed men with incomplete follow-up had higher ASA-score and impaired testicular function at 
baseline: higher proportion of T below 8 nmol/L, higher LH and LH/T-ratio. In the unexposed 
group there was no difference in baseline characteristics between those that completed the study 
versus those that did not, which may result in an overestimation of the testicular recovery of the 
exposed group. The unexposed group surprisingly had decreasing levels of T, which complicates 
the comparison.  
 
At baseline serum T levels were lower than expected, median 11 nmol/L, whereas the EMAS study 
(n=2736) showed a mean of 16.5 nmol/L.130 In comparison, young healthy males participating in 
the Framingham Heart Study had a median (quartile range) serum T of 24.2 (10.3) nmol/L .251 The 
diagnosis of RC may in itself be a reason for low serum T levels, as psychological stress is known 
to have a negative impact on serum T levels.267-269 The inflammatory reaction to the tumor may 
also adversely impact T levels.270, 271 Prostate cancer patients of comparable age have been shown 
to have low T baseline levels (n = 25, 10.6 ± 0.94 nmol/L).272 However, the median T levels after 
two years in the treated men returned to baseline levels. As T levels have diurnal fluctuation and 
are dependent on feeding and sexual habits, standardized sampling is important (fasting morning 
sample, no sexual activity). Serum T levels may decrease approximately 30% if eating before 
sampling and serum T seems to increase with sexual activity.273-276 Collection of blood samples and 
laboratory analyses for androgen assessment were done according to the guidelines of the 
Endocrine Society. The used longitudinal regression analysis accounts for the covariance of 
repeated samples in the study population and final models were adjusted for important 
confounders and effect modifiers.  
 
The oncological and AE analysis were based on a subgroup thus not following the design of the 
original trial. The results should be validated in dedicated studies. However, the respective sub-
groups did not differ in essential baseline- or perioperative characteristics or TD. As for image 
analysis, the intra-observer variability was low (<2 %).  
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Future perspectives 
The findings of postoperative implications of testicular failure due to RT promotes a study 
designed to follow hormone levels during the pre- and postoperative period to validate the 
current finding as well as develop understanding of hormonal impact in wound healing. The 
next step is to investigate if TRT might be of value in the perioperative period in men with 
adversely impacted T levels. 
Evaluation of muscle mass as a possible marker for hypogonadism in men lacking possibility 
to express the typical symptoms needs to be evaluated in a dedicated study, and if successful 
could be integrated in the ordinary follow-up in RC patient treatment. 
Sarcopenic signs, or muscle mass loss, as well as increased LH as markers for occult 
metastases or cancer recurrence may complement current practice as it seems they predate 
metastatic detection by current methods. 
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Conclusions 
Overall conclusion 
Testicular endocrine function is threatened by RT, with both short- and long-term implications, 
and the testes should be considered an organ at risk in sRT as they currently are in CRT. 
 
Specific conclusions 
 
- Abdominal and pelvic muscles are as responsive to androgens as appendicular muscles in 
young healthy men, with clear dose-response relationship. Changes are clearly evaluated 
on MRI. 
 
- Radiotherapy treatment in RC results in impact on the hypothalamic-pituitary-gonadal axis, 
related to TD. Average T level are regained within two years after surgery but select 
patients does not recover and signs of compensated hypogonadism is increased. Increased 
LH after one-year is associated with cancer recurrence. 
 
- Decline in preoperative levels of T due to RT is a risk factor for adverse postoperative 
adverse events graded 3+ according to Clavien-Dindo. This could hypothetically explain 
in part why men suffer more postoperative complications than women. 
 
- Abdominal and PM muscle area are androgen dependent in older men with RC, and 
decrease in total abdominal muscle area is related to later metastatic disease. Data can be 
evaluated using routine radiologic examinations and might be of clinical as well as 
prognostic value.  
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Sammanfattning på svenska 
Rektalcancer, den åttonde vanligaste cancerformen i Sverige, drabbar ca 2100 personer per 
år. Fler män än kvinnor insjuknar i rektalcancer. Rektalcancer definieras med att tumören 
sitter inom 15 cm från ändtarmsöppningen. Behandlingen är i första hand kirurgisk, med 
avlägsnande av mer eller mindre av rektum inklusive tumör, omkringliggande blod- och 
lymfkärl, lymfknutor och en viss marginal av vävnad. Man strävar efter att följa embryonala 
strukturer för att minimera risk för att cancerceller finns kvar samt att minska blödning och 
nervskador. Beroende på tumörens läge och omfattning kan hela rektum inklusive 
tarmöppningen behöva tas med, vilket nödvändiggör permanent stomi, i annat fall kan tarmen 
sys ihop i en s.k. anastomos. I modern rektalcancerbehandling ingår ofta preoperativ 
strålbehandling, som i sig visats sänka risken för lokalrecidiv med ca 50%. Dock medför 
strålbehandling diverse bieffekter, däribland risk för testikeldysfunktion och påverkade 
hormonnivåer. 
 
Denna avhandling redogör för testosterons effekter i kroppen och sätter det i relation till 
strålterapi. 
 
Studie I genomfördes i Boston, med material från en randomiserad kontrollerad studie och 
analyserade effekterna av olika doser av administrerad testosteron på muskler i buk och 
bäcken hos yngre friska män. Inga tidigare studier har genomförts med sådant material och 
med MR som metod. Skelettmusklers relation till det anabola hormonet testosteron är väl 
studerat i framförallt armar och ben samt i ”fettfri vävnad” vilket dock inkluderar bukens 
organ. Studien kunde påvisa ett dos-beroende samband mellan muskelarea, vilket har visats 
relatera till total kroppsmuskelmassa, och testosteron. Detta möjliggör fortsatta studier och 
tanken att kunna behandla svaghet i dessa muskler, som kan innebära dålig balans och ökad 
risk för fall liksom bäckenbottenproblematik, med testosteron. 
 
Studie II-IV arbetade med ett material från en kohortstudie inkluderande rektal- och 
prostatacancerpatienter i Stockholm.  
Studie II tog vid en tidigare studie som påvisat akut testikeldysfunktion efter strålningsterapi. 
I den strålade gruppen så återgick den mediala testosteronnivån till samma nivå som innan 
behandling inom två år. Dock så var luteiniserande hormon, det hormon som styr 
testosteronnivån, påverkat på ett sådan sätt som tyder på att testiklarna i snitt inte var helt 
återställda. Vidare så fanns det en relation mellan förhöja nivåer av luteiniserande hormon ett 
år efter kirurgisk behandling och ökad risk för cancerrecidiv. 
I studie III så undersöktes risken för svåra postoperativa komplikationer i relation till 
minskade nivåer av testosteron på grund av strålning. En testosteronminskning innebar en 
nivåberoende ökad risk för svåra postoperativa komplikationer, detta oberoende på andra 
behandlingsmässiga faktorer, såsom typ av kirurgi. 
Studie IV validerade en tidigare pilotstudie från kohorten och fann samband mellan fritt 
testosteron och muskelarea mätt på CT eller MR. Detta ger att samband mellan androgener 
och bukmuskler gäller även i denna grupp av i snitt äldre män med cancersjukdom. Vidare 
var minskande muskelarea under första året efter operation relaterad till systemiskt 
recidiverande cancersjukdom. 
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